Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
MAMMALIAN NUCLEAR RECEPTOR COFACTORS CF7 AND CF8 AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2002/042322
Kind Code:
A2
Abstract:
The present invention relates to novel nuclear receptor cofactors which we call CF7 and CF8, the isolated nucleic acid sequences thereof and the isolated proteins thereof. The invention further relates to processes for isolating and/or producing the nucleic acids or the proteins as well as methods of use of these cofactors, such as inhibiting or activating the binding of the cofactors to the nuclear receptor.

Inventors:
Jackson, David (Schröderstrasse 61 Heidelberg, 69120, DE)
Casari, Georg (Hauptstr. 313 Eppelheim, 69214, 5)
Suckow, Jörg (Uhlandstr. 5 Dossenheim, 69221, DE)
Application Number:
PCT/EP2001/013548
Publication Date:
May 30, 2002
Filing Date:
November 21, 2001
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
LION BIOSCIENCE AG (Im Neuenheimer Feld 515 Heidelberg, 69120, DE)
Jackson, David (Schröderstrasse 61 Heidelberg, 69120, DE)
Casari, Georg (Hauptstr. 313 Eppelheim, 69214, 5)
Suckow, Jörg (Uhlandstr. 5 Dossenheim, 69221, DE)
International Classes:
C07K14/47; G01N33/50; (IPC1-7): C07K14/00
Domestic Patent References:
WO1999063071A21999-12-09
Other References:
DATABASE EMBL [Online] 1 November 1996 (1996-11-01) NEHLS ET AL.: "C1D DNA-BINDING PROTEIN (NUCLEAR DNA-BINDING PROTEIN)" Database accession no. Q13901 XP002197777 & NEHLS ET AL.: "cDNA cloning, recombinant expression and characterization of polypeptides with exceptional DNA affinity" NUCLEIC ACIDS RESEARCH, vol. 26, no. 26, 1998, pages 1160-1166,
DATABASE EMBL [Online] 15 May 2000 (2000-05-15) BROWN, A.: "Human DNA sequence from clone RP11-369J21 on chromosome 10" Database accession no. AL356095 XP002197778
DATABASE EMBL [Online] 6 October 2000 (2000-10-06) DUMAS ET AL.: "Human secreted protein, SEQ ID NO: 5312" Database accession no. AAG01231 XP002197779
Attorney, Agent or Firm:
Ziebig, Marlene K. (Gulde Hengelhaupt Ziebig Schützenstr. 15-17 Berlin, 10117, DE)
Download PDF:
Claims:
CLAIMS :
1. An isolated nucleic acid molecule coding for a nuclear receptor cofactor which is selected from the group comprising: a) the nucleotide sequence set forth in SEQ ID NOs: 1 and/or 4; b) or a complement thereof as set forth in SEQ ID NOs: 2 and/or 5, c) a nucleic acid which hybridizes to a nucleic acid having a nucleotide sequence which is the complement of the nucleotide sequence of SEQ ID NOs 1 and/or 4 under conditions of high stringency, and d) a nucleic acid which hybridizes to a nucleic acid having a nucleotide sequence which is the complement of the nucleotide sequence of SEQ ID NOs: 2 and/or 5 under conditions of high stringency.
2. The isolated nucleic acid molecule of claim 1 which is genomic DNA.
3. The isolated nucleic acid molecule of claim 1 which is cDNA.
4. The isolated nucleic acid molecule of claim 1 which is RNA.
5. An isolated nucleic acid molecule comprising the nucleic acid molecule of any of claims 1 to 4 and a label attached thereto.
6. A vector comprising the nucleic acid molecule of claim 1.
7. The vector of claim 6, which is an expression vector.
8. A host cell transfected with the vector of claim 6 or 7.
9. A host cell transfected with the expression vector of claim 7.
10. A method of producing a polypeptide comprising the step of culturing the host cell of claim 9 in an appropriate culture medium to, thereby, produce the polypeptide.
11. An isolated polypeptide encoded by any portion of the nucleic acid of claim 1.
12. An isolated polypeptide selected from the group comprising: the amino acid sequences set forth in SEQ ID NOs. 3 and/or 6.
13. A method for screening for agents which are capable of inhibiting the cellular function of the cofactor CF7 and/or CF8, comprising the steps of: a) contacting one or more candidate agents with a polypeptide according to claims 11,12 b) removing unbound agent (s) c) detecting whether the agent (s) interact with the polypeptide of the cofactor.
14. A method for inhibiting or activating the cellular function of the cofactor CF7 and/or CF8, comprising the steps of: a) contacting a cell with a binding agent that binds the polypeptide according to claim 11,12, b) whereby the cellular function of CF7 and/or CF8 is inhibited or activated.
15. Method according to claim 13 or 14, characterized in that the binding agent or the candidate agent is an antibody.
16. Method according to claim 13 or 14, characterized in that the binding agent or the candidate agent is RNA.
17. Method according to claim 13 or 14, characterized in that the binding agent or the candidate agent is an antisense oligonucleotide.
18. Method according to claim 13 or 14, characterized in that the binding agent or the candidate agent is a ribozyme.
19. Method according to claim 13 or 14, characterized in that the binding agent or the candidate agent is a steroid molecule.
20. Method according to claim 14, characterized in that the cell is in a body.
21. Method for obtaining a full length cDNA sequence of the CF7 gene, wherein a nucleic acid according to SEQ ID No. 1,2,7 and/or 8 is used to screen a mRNA library, wherein positive clones are sequenced and wherein the fulllength sequence is assembled by alignment to each other and/orto SEQ ID NO. 1.
22. Nucleic acid sequence obtained when applying the method according to claim 21.
23. Method for obtaining a full length cDNA sequence of the CF8 gene, wherein a nucleic acid according to SEQ ID No. 4,5,9 and/or 10 is used to screen a mRNA library, wherein positive clones are sequenced and wherein the fulllength sequence is assembled by alignment to each other and/or to SEQ ID NO. 4.
24. Nucleic acid sequence obtained when applying the method according to claim 23.
Description:
MAMMALIAN NUCLEAR RECEPTOR COFACTORS CF7 AND CF8 AND METHODS OF USE BACKGROUND OF THE INVENTION NUCLEAR RECEPTORS Multicellular organisms are dependent on advanced mechanisms of information transfer between cells and body compartments. The information that is transmitted can be highly complex and can result in the alteration of genetic programs involved in cellular differentiation, proliferation, or reproduction. The signals, or hormones, are often simple molecules, such as peptides, fatty acid, or cholesterol derivatives.

Many of these signals produce their effects by ultimately changing the transcription of specific genes. One well-studied group of proteins that mediate a cell's response to a variety of signals is the family of transcription factors known as nuclear receptors, hereinafter referred to frequently as"NR". Members of this group include receptors for steroid hormones, vitamin D, ecdysone, cis and trans retinoic acid, thyroid hormone, bile acids, cholesterol-derivatives, fatty acids (and other peroxisomal proliferators), as well as so-called orphan receptors, proteins that are structurally similar to other members of this group, but for which no ligands are known (Escriva, H. et al., Ligand binding was acquired during evolution of nuclear receptors, PNAS, 94,6803-6808,1997). Orphan receptors may be indicative of unknown signaling pathways in the cell or may be nuclear receptors that function without ligand activation. The activation of transcription by some of these orphan receptors may occur in the absence of an exogenous ligand and/or through signal transduction

pathways originating from the cell surface (Mangelsdorf, D. J. et al., The nuclear receptor superfamily : the second decade, Cell 83,835-839,1995).

In general, three functional domains have been defined in NRs. An amino terminal domain is believed to have some regulatory function. A DNA-binding domain hereinafter referred to as"DBD"usually comprises two zinc finger elements and recognizes a specific Hormone Responsive Element hereinafter referred to as"HRE" within the promoters of responsive genes. Specific amino acid residues in the"DBD" have been shown to confer DNA sequence binding specificity (Schena, M. & Yamamoto, K. R., Mammalian Glucocorticoid Receptor Derivatives Enhance Transcription in Yeast, Science, 241: 965-967,1988). A Ligand-binding-domain hereinafter referred to as"LBD"is at the carboxy-terminal region of known NRs. In the absence of hormone, the LBD appears to interfere with the interaction of the DBD with its HRE. Hormone binding seems to result in a conformational change in the NR and thus opens this interference (Brzozowski et al., Molecular basis of agonism and antagonism in the oestogen receptor, Nature, 389,753-758,1997; Wagner et al., A structural role for hormone in the thyroid hormone receptor, Nature, 378,690-697.

1995). A NR without the HBD constitutively activates transcription but at a low level.

Both the amino-terminal domain and the LBD of the NR appear to have transcription activation functions hereinafter referred to as"TAF". Acidic residues in the amino- terminal domains of some nuclear receptors may be important for these transcription factors to interact with RNA polymerase. TAF activity may be dependent on interactions with other protein factors or nuclear components (Diamond et al., Transcription Factor Interactions : Selectors of Positive or Negative Regulation from a Single DNA Element, Science, 249: 1266-1272,1990). Certain oncoproteins (e. g., c- Jun and c-Fos) can show synergistic or antagonistic activity with glucocorticoid receptors (GR) in transfected cells. Furthermore, the receptors for estrogen and vitamins A and D, and fatty acids have been shown to interact, either physically or functionally, with the Jun and Fos components of AP-1 in the transactivation of steroid-or AP-1 regulated genes.

Nuclear receptor modulators like steroid hormones affect the growth and function of specific cells by binding to intracellular receptors and forming nuclear receptor-ligand

complexes. Nuclear receptor-hormone complexes then interact with a hormone response element (HRE) in the control region of specific genes and alter specific gene expression.

COFACTORS OF NUCLEAR RECEPTORS Coactivators or transcriptional activators are proposed to bridge between sequence specific transcription factors, the basal transcription machinery and in addition to influence the chromatin structure of a target cell. Several proteins like SRC-1, ACTR, and Grip1, which are also cofactors of NRs similar to that disclosed in this invention, interact with NRs in a ligand enhanced manner (Heery et al., A signature motif in transcriptional coactivators mediates binding to nuclear receptors, Nature, 387,733- 736; Heinzel et al., A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression, Nature 387,43-47,1997). Furthermore, the physical interaction with negative receptor-interacting proteins or co-repressors has been demonstrated (Xu et al., Coactivator and Corepressor complexes in nuclear receptor function, Curr Opin Genet Dev, 9 (2), 140-147,1999).

A number of potential factors interacting with nuclear hormone receptors have been described. The majority interact with the ligand binding domain of nuclear receptors in a ligand enhanced manner. The coactivators can be grouped into several classes including the SRC, Grip and ACTR family. These proteins stimulate transcriptional activity of hormone receptors. These coactivators interact with the receptor through a highly conserved motif, the nuclear receptor box (LXXLL). This motif is of importance in the ligand dependent receptor/coactivator interaction. A typical member of this class of proteins is PGC-1. The protein interacts with several nuclear receptors e. g. the PPAR gamma, the estradiol receptor (ER) and the glucocorticoid receptor (GR).

The present invention relates to the identification of two novel nuclear receptor cofactors.

The present invention provides novel proteins, nucleic acids, and methods useful for developing and identifying compounds for the treatment of such diseases and disorders as, hormonal dysfunctions, and others not specifically mentioned here.

The novel proteins which interact in vivo with a nuclear receptor shall hereinafter be referred to as"cofactor"or also CF7 and CF8 protein.

Identified and disclosed herein are protein sequences for novel cofactors and the nucleic acid sequences encoding these cofactors, which we call CF7 and CF8. The importance of this invention is manifested in the effect of CF7 and CF8 to modulate genes involved in cellular functions like regulation of metabolism and cell homeostasis, cell proliferation and differentiation, pathological cellular aberrations, or cellular defense mechanisms.

In one aspect of the present invention, we provide isolated nucleic acid sequences for the novel CF7 cofactor. In particular, we provide the cDNA sequences encoding human CF7.

These nucleic acid sequences have a variety of uses. For example, they are useful for making vectors and for transforming cells, both of which are ultimately useful for production of the CF7 and the CF8 protein.

They are also useful as scientific research tools for developing nucleic acid probes for determining expression levels of the cofactor genes, e. g., to identify diseased or otherwise abnormal states. The are particularly useful for diagnostic purposes to, e. g. identify deleted or mutant CF7 and/or CF8 genes; or measure expression thereof.

They are useful for developing analytical tools such as anti sense oligonucleotides for selectively inhibiting expression of the cofactor gene to determine physiological responses.

In another aspect of the present invention, we provide a homogenous composition comprising the cofactor protein CF7 and/or CF8. The protein is useful for screening drugs for agonist and antagonist activity, and, therefore, for screening for drugs useful in regulating physiological responses associated with the cofactors according to the invention. The proteins are also useful for developing antibodies for detection of the proteins.

Flowing from the foregoing are a number of other aspects of the invention, including (a) vectors, such as plasmids, comprising the cofactor nucleic acid sequences that may further comprise additional regulatory elements, e. g., promoters, (b) transformed cells that express the cofactors, (c) nucleic acid probes, (d) antisense oligonucleotides, (e) agonists, (f) antagonists, and (g) transgenic mammals. Further aspects of the invention comprise methods for making and using the foregoing compounds and compositions.

The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS THE CF7 AND CF8 PROTEINS AND NUCLEIC ACIDS : Nuclear hormone receptors are potent repressors of transcription in the unliganded state. We describe here nuclear receptor corepressors that we call CF7 and CF8, which show homology to the previously described nuclear hormone receptor corepressors SUN-CoR (Small Unique Nuclear receptor CoRepressor) (Zamir et al., Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14400-14405, December 1997) and are highly basic. CF7 and CF8 potentiate transcriptional repression by thyroid hormone receptor and RevErb in vivo, possibly represses transcription when fused to a heterologous DNA binding domain, and may interact with RevErb as well as with thyroid hormone receptor in vitro. We conclude that CF/and CF8 are corepressors and may function as an additional component of the complex involved in transcriptional repression by unliganded and orphan nuclear hormone receptors.

The present invention comprises, in part, novel CF cofactors. Particularly preferred embodiments of these cofactors having an amino acid sequence substantially the same as SEQ ID NO. 3 for CF7 and SEQ ID NO. 6 for CF8. As used herein, if reference to the cofactor is made or the cofactor"X", wherein"X"stands for the

number designating the cofactor, it is meant as a reference to any protein having an amino acid sequence substantially the same as SEQ ID NO. 3 and SEQ ID NO. 6.

The present invention also comprises the nucleic acid sequence encoding the cofactors which nucleic acid sequences are substantially the same as SEQ ID NO. 1 and SEQ ID NO. 4 encoding human cofactors as preferred embodiment and/or the complements thereof as shown in SEQ ID NO. 2 and SEQ ID NO. 5 (see also figures, all nucleic acid sequences are written in 5'-3'orientation). In one embodiment, the nucleic acid sequences according to the invention comprises the sequences according to SEQ ID NO. 1,2,4 and/or 5, in a preferred embodiment nucleic acid sequences according to the invention consist of the sequences according to SEQ ID NO. 1,2,4 and/or 5.

Herein the"complement"refers to the complementary strand of the nucleic acid according to the invention, thus the strand that would hybridize to the nucleic acid according to the invention. In accordance with standard biological terminology all DNA sequences herein are written in 5'-3'orientation, thus the complements depicted (see also figures) are actually"reverse"complements (as also stated in the figures). For simplification purposes they are however often referred to simply as "complement"herein.

As used herein, a protein"having an amino acid sequence substantially the same as SEQ ID NO x" (where"x"is the number of one of the protein sequences recited in the Sequence Listing) means a protein whose amino acid sequence is the same as SEQ ID NO x or differs only in a way such that at least 50% of the residues compared in a sequence alignment with SEQ ID NO. x are identical, preferably 75% of the residues are identical, even more preferably 95% of the residues are identical and most preferably at least 98% of the residues are identical Those skilled in the art will appreciate that conservative substitutions of amino acids can be made without significantly diminishing the proteins'affinity for interacting proteins, nuclear receptors, DNA binding sites, cofactor modulators, e. g. small molecular hydrophobic compounds, or RNA.

Other substitutions may be made that increase the proteins'affinity for these compounds. Making and identifying such proteins is a routine matter given the teachings herein, and can be accomplished, for example, by altering the nucleic acid sequence encoding the protein (as disclosed herein), inserting it into a vector, transforming a cell, expressing the nucleic acid sequence, and measuring the binding affinity of the resulting protein, all as taught herein.

As used herein the term"a molecule having a nucleotide sequence substantially the same as SEQ ID NO y" (wherein"y"is the number of one of the protein-encoding nucleotide sequences listed in the sequence listing) means a nucleic acid encoding a protein"having an amino acid sequence substantially the same as SEQ ID NO y+l" (wherein"y+l"is the number of the amino acid sequence for which nucleotide sequence"y"codes) as defined above. This definition is intended to encompass natural allelic variations in the CF7 and CF8 sequence. Cloned nucleic acids provided by the present invention may encode the CF7 and CF8 proteins of any species of origin, including (but not limited to), for example, mouse, rat, rabbit, hamster, cat, dog, pig, primate, and human.

Preferably the nucleic acids provided by the invention encode CF7 and CF8 of mammalian most preferably human origin.

IDENTIFICATION OF VARIANTS AND HOMOLOGUES AS WELL AS USE OF PROBES: Nucleic acid hybridization probes provided by the invention are nucleic acids consisting essentially of the nucleotide sequences complementary to the sequence depicted in SEQ ID NO. 1 and 4 and/or the complement thereof as shown in SEQ ID NO. 2 and 5, or parts thereof which are effective in nucleic acid hybridization (see listing Fig. 4).

Nucleic acid hybridization probes provided by the invention are nucleic acids capable of detecting i. e. hybridizing to the gene encoding the polypeptide according to SEQ ID NO. 3 and SEQ ID NO. 6.

Nucleic acid probes are useful for detecting CF7 or CF8 gene expression in cells and tissues using techniques well-known in the art, including, but not limited to, Northern blot hybridization, in situ hybridization, and Southern hybridization to reverse transcriptase-polymerase chain reaction product DNAs. The probes provided by the present invention, including oligonucleotide probes derived therefrom, are also useful for Southern hybridization of mammalian, preferably human, genomic DNA for screening for restriction fragment length polymorphism (RFLP) associated with certain genetic disorders. As used herein, the term complementary means a nucleic acid having a sequence that is sufficiently complementary in the Watson-Crick sense to a target nucleic acid to bind to the target under physiological conditions or experimental conditions those skilled in the art routinely use when employing probes.

It is understood in the art that a nucleic acid sequence will hybridize with a complementary nucleic acid sequence under high stringent conditions as defined herein, even though some mismatches may be present. Such closely matched, but not perfectly complementary sequences are also encompassed by the present invention. For example, differences may occur through genetic code degeneracy, or by naturally occurring or man made mutations and such mismatched sequences would still be encompassed by the present claimed invention.

Preferably, the nucleotide sequences of the nuclear cofactor SEQ ID NO : 1 and 4 and/or their complements (SEQ ID NO. 2 and 5) can be used to derive oligonucleotide fragments (probes) of various length. Stretches of 17 to 30 nucleotides are used frequently but depending on the screening parameters longer sequences as 40,50,100,150 up to the full length of the sequence may be used.

Those probes can be synthesized chemically and are obtained readily from commercial oligonucleotide providers. Chemical synthesis has improved over the years and chemical synthesis of oligonucleotides as long as 100-200 bases is possible. The field might advance further to allow chemical synthesis of even longer fragments. Alternatively, probes can also be obtained by biochemical de novo synthesis of single stranded DNA. In this case the nucleotide sequence of the nuclear receptor cofactor or its complement serves as a template and the corresponding complementary strand is synthesized. A variety of standard techniques such as nick translation or primer extension from specific primers or short

random oligonucleotides can be used to synthesize the probe (Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular cloning : a laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, 1989)). Nucleic acid reproduction technologies exemplified by the polymerase chain reaction (Saiki, R. K. et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487-491 (1988)) are commonly applied to synthesize probes. In the case of techniques using specific primers the nucleic acid sequences of the cofactor or its complement are not only used as a template in the biochemical reaction but also to derive the specific primers which are needed to prime the reaction.

In some cases one might also consider to use the nucleic acid sequence of the cofactor or its complement as a template to synthesize an RNA probe. A promoter sequence for a DNA-dependent RNA polymerase has to be introduced at the 5'-end of sequence. As an example this can be done by cloning the sequence into a vector which carries the respective promoter sequence. It is also possible to introduce the needed sequence by synthesizing a primer with the needed promoter in the form of a 5'"tail". The chemical synthesis of a RNA probe is another option.

Appropriate means are available to detect the event of a hybridization. There is a wide variety of labels and detection systems, e. g. radioactive isotopes, fluorescent, or chemiluminescent molecules which can be linked to the probe. Furthermore, there are methods of introducing haptens which can be detected by antibodies or other ligands such as the avidin/biotin high affinity binding system.

Hybridization can take place in solution or on solid phase or in combinations of the two, e. g. hybridization in solution and subsequent capture of the hybridization product onto a solid phase by immobilized antibodies or by ligand coated magnetic beads.

Hybridization probes act by forming selectively duplex molecules with complementary stretches of a sequence of a gene or a cDNA. The selectivity of the process can be controlled by varying the conditions of hybridization. To select sequences which are identical highly homologous to the sequence of interest stringent conditions for the hybridization will be used, e. g. low salt in the range of 0.02 M to 0.15 M salt and/or high temperatures in the range from 50°C degrees centigrade to 70°C degrees

centigrade. Stringency can be further improved by the addition of formamide to the hybridization solution. The use of stringent conditions which means that only little mismatch or a complete match will lead to a hybridization product would be used to isolate closely related members of the same gene family. Thus, as used herein stringent hybridization conditions are those where between 0.02 M to 0.15 M salt and/or high temperatures in the range from 50°C degrees centigrade to 70°C degrees centigrade are applied.

The use of highly stringent conditions or conditions of"high stringency"means that only very little mismatch or a complete match which lead to a hybridization product would be used to isolate very closely related members of the same gene family.

Thus, as used herein highly stringent hybridization conditions are those where between 0.02-0.3 M salt and 65°C degrees centigrade are applied for about 5 to 18 hours of hybridization time and additionally, the sample filters are washed twice for about 15 minutes each at between 60°C-65°C degrees centigrade, wherein the first washing fluid contains about 0.1 M salt (NaCI and/or Sodium Citrate) and the second contains only about 0.02 M salt (NaCI and/or Sodium Citrate). In a preferred embodiment the following conditions are considered to be highly stringent: Hybridisation in a buffer containing 2 x SSC (0.03 M Sodium Citrate, 0.3 M NaCI) at 65°C-68°C degrees centigrade for 12 hours, followed by a washing step for 15 minutes in 0.5 x SSC, 0.1% SDS, and a washing step for 15 minutes at 65°C degrees centigrade in 0.1 x SSC, 0.1% SDS.

Less stringent hybridization conditions, e. g. 0.15 M salt-1 M salt and/or temperatures from 22°C degrees centigrade to 56°C degrees centigrade are applied in order to detect functionally equivalent genes in the same species or for orthologous sequences from other species.

Unspecific hybridization products are removed by washing the reaction products repeatedly in 2 x SSC solution and increasing the temperature.

DEGENERATE PCR AND CLONING OF HOMOLOGUES The nucleotide sequences of the cofactor CF7 and CF8 or their complements can be used to design primers for a polymerase chain reaction (see also examples of such primers in Fig. 1). Due to the degeneracy of the genetic code the respective amino acid sequence is used to design oligonucleotides in which varying bases coding for the same amino acid are included. Numerous design rules for degenerate primers have been published (Compton et al, 1990). As in hybridization there are a number of factors known to vary the stringency of the PCR. The most important parameter is the annealing temperature. To allow annealing of primers with imperfect matches annealing temperatures are often much lower than the standard annealing temperature of 55°C, e. g. 35°C to 52°C degrees can be chosen. PCR reaction products can be cloned. Either the PCR product is cloned directly, with reagents and protocols from commercial manufacturers (e. g. from Invitrogen, San Diego, USA).

Alternatively, restriction sites can be introduced into the PCR product via a 5'-tail of the PCR primers and used for cloning. PCR fragments may be generated using also the primers shown in figure 1 (SEQ ID No. 7 and 8 for CF7 and SEQ ID NO. 9 and 10 for CF8).

GENETIC VARIANTS Fragments from the nucleotide sequence of the cofactor or its complement can be used to cover the whole sequence with overlapping sets of PCR primers. These primers are used to produce PCR products using genomic DNA from a human diversity panel of healthy individuals or genomic DNA from individuals which are phenotypically conspicuous. The PCR products can be screened for polymorphisms, for example by denaturing gradient gel electrophoresis, binding to proteins detecting mismatches or cleaving heteroduplices or by denaturing high-performance liquid chromatography. Products which display mutations need to be sequenced to identify the nature of the mutation. Alternatively, PCR products can be sequenced directly omitting the mutation screening step to identify genetic polymorphisms. If genetic variants are identified and are associated with a discrete phenotype, these genetic variations can be included in diagnostic assays. The normal variation of the human

population is of interest in designing screening assays as some variants might interact better or worse with a respective lead, ie. therapeutic or potentially therapeutic substance (a pharmacodynamic application). Polymorphisms or mutations which can be correlated to phenotypic outcome are a tool to extend the knowledge and the commercial applicability of the nucleotide sequences of the cofactors CF7 and CF8 or their complements or their gene products, as variants might have a slightly different molecular behavior or desired properties. Disease- causing mutations or polymorphisms allow the replacement of this disease inducing gene copy with a wild-type copy by means of gene therapy approaches and/or the modulation of the activity of the gene product by drugs.

PREPARATION OF POLYNUCLEOTIDES AND/OR THE FULL-LENGTH cDNA : DNA which encodes cofactor CF7 and/or CF8 may be obtained, in view of the instant disclosure, by chemical synthesis, by screening reverse transcripts of mRNA from appropriate cells or cell line cultures, by screening genomic libraries from appropriate cells, or by combinations of these procedures, as illustrated below.

Screening of mRNA or genomic DNA may be carried out with oligonucleotide probes generated from the CF nucleotide sequences information provided herein, or the primers in Fig. 1 can be used.

Probes may be labeled with a detectable group such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with known procedures and used in conventional hybridization assays, as described in greater detail in the Examples below. Alternatively, the CF7 AND/OR CF8 nucleotide sequences may be obtained by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers being produced from the CF nucleotide sequences provided herein, according to SEQ ID NO 1 or 4 and/or their complements as shown in SEQ ID NO. 2 or 5, or parts thereof.

Upon purification or synthesis, the nucleic acid according to the invention may be labeled, e. g. for use as a probe.

As single and differential labeling agents and methods, any agents and methods which are known in the art can be used. For example, labels may consist of the group comprising enzymes such as p-galactosidase, alkaline phosphatase and peroxidase, enzyme substrates, coenzymes, dyes, chromophores, fluorescent, chemiluminescent and bioluminescent labels such as FITC, Cy5, Cy5.5, Cy7, Texas- Red and IRD40 (Chen et al. (1993), J. Chromatog. A 652: 355-360 and Kambara et al. (1992), Electrophoresis 13: 542-546), ligands or haptens such as biotin, and radioactive isotopes such as 3H, 35S, 32p 1251 and 14C.

EXPRESSION OF THE CF7 AND/OR CF8 PROTEIN/POLYPETIDES : The CF nucleic acids or polypeptides may be synthesized in host cells transformed with a recombinant expression construct comprising a nucleic acid encoding the cofactor according to the invention. Such a recombinant expression construct can also be comprised of a vector that is a repliable DNA construct.

Amplification vectors do not require expression control domains. All that is needed is the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants. See, Sambrook et al., Molecular Cloning : A Laboratory Manual (2nd Edition, Cold Spring Harbor Press, New York, 1989).

An expression vector comprises a polynucleotide operatively linked to a prokaryotic promoter. Alternatively, an expression vector is a polynucleotide operatively linked to an enhancer-promoter that is a eukaryotic promoter, and the expression vector further has a polyadenylation signal that is positioned 3'of the carboxy-terminal amino acid and within a transcriptional unit of the encoded polypeptide. A promoter is a region of a DNA molecule typically within about 500 nucleotide pairs in front of (upstream of) the point at which transcription begins (i. e., a transcription start site). In general, a vector contains a replicon and control sequences which are derived from species compatible with the host cell. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells.

Another type of discrete transcription regulatory sequence element is an enhancer.

An enhancer provides specificity of time, location and expression level for a particular encoding region (e. g., gene). A major function of an enhancer is to increase the level of transcription of a coding sequence in a cell.

As used herein, the phrase"enhancer-promoter"means a composite unit that contains both enhancer and promoter elements. An enhancer-promoter is operatively linked to a coding sequence that encodes at least one gene product.

An enhancer-promoter used in a vector construct of the present invention may be any enhancer-promoter that drives expression in a prokaryotic or eukaryotic cell to be transformed/transfected.

A coding sequence of an expression vector is operatively linked to a transcription terminating region. RNA polymerase transcribes an encoding DNA sequence through a site where polyadenylation occurs.

An expression vector that comprises a polynucleotide that encodes the polypeptide of the cofactors CF7 or CF8. Such a polynucleotide is meant to include a sequence of nucleotide bases encoding a CF7 or CF8 polypeptide sufficient in length to distinguish said segment from a polynucleotide segment encoding a non-cofactor polypeptide.

A polypeptide of the invention may also encode biologically functional polypeptides or peptides which have variant amino acid sequences, such as with changes selected based on considerations such as the relative hydropathic score of the amino acids being exchanged.

These variant sequences are those isolated from natural sources or induced in the sequences disclosed herein using a mutagenic procedure such as site-directed mutagenesis.

Furthermore, an expression vector of the present invention may contain regulatory elements for optimized translation of the polypeptide in prokaryotic or eukaryotic

systems. These sequences are operatively located around the transcription start site and are most likely similar to ribosome recognition sites like prokaryotic ribosome binding sites (RBS) or eukaryotic Kozak sequences as known in the art (Kozak M., Initiation of translation in prokaryotes and eukaryotes. Gene 234,187-208 (1999)).

An expression vector of the present invention is useful both as a means for preparing quantities of the CF7 or CF8 polypeptide-encoding DNA itself, and as a means for preparing the encoded CF7 or CF8 polypeptide and peptides. It is contemplated that where cofactor polypeptides of the invention are made by recombinant means, one may employ either prokaryotic or eukaryotic expression vectors as shuttle systems.

Where expression of recombinant CF7 or CF8 polypeptide is desired and a eukaryotic host is contemplated, it is most desirable to employ a vector such as a plasmid, that incorporates a eukaryotic origin of replication. Additionally, for the purposes of expression in eukaryotic systems, one desires to position the cofactor encoding sequence or if desired parts thereof adjacent to and under the control of an effective eukaryotic promoter. To bring a coding sequence under control of a promoter, whether it is eukaryotic or prokaryotic, what is generally needed is to position the 5'end of the translation initiation site of the proper translational reading frame of the polypeptide between about 1 and about 2000 nucleotides 3'of or downstream with respect to the promoter chosen.

Furthermore, where eukaryotic expression is anticipated, one would typically desire to incorporate into the transcriptional unit which includes the CF7 or CF8 polypeptide, an appropriate polyadenylation site.

The invention provides homogeneous compositions of mammalian cofactor polypeptides produced by transformed prokaryotic or eukaryotic cells as provided herein. Such homogeneous compositions are intended to be comprised of mammalian cofactor protein that comprises at least 90% of the protein in such homogenous composition. The invention also provides membrane preparation from cells expressing the mammalian cofactors polypeptides as the result of transformation with a recombinant expression construct, as described here.

Within the scope of the present invention the terms recombinant protein or coding sequence both also include tagged versions of the proteins depicted in SEQ ID NO. 3 or 6 and/or and fusion proteins of said proteins with any other recombinant protein.

Tagged versions here means that small epitopes of 3-20 amino acids are added to the original protein by extending the coding sequence either at the 5 or the 3'terminus leading to N-terminal or C-terminal extended proteins respectively, or that such small epitopes are included elsewhere in the protein. The same applies for fusion proteins where the added sequences are coding for longer proteins, varying between 2 and 100 kDa. Tags and fusion proteins are usually used to facilitate purification of recombinant proteins by specific antibodies or affinity matrices or to increase solubility of recombinant proteins within the expression host. Fusion proteins are also of major use as essential parts of yeast two hybrid screens for interaction partners of recombinant proteins.

Tags used in the scope of the present invention may include but are not limited to the following : EEF (alpha Tubulin), B-tag (QYPALT), E tag (GAPVPYPDPLEPR) c-myc Tag (EQKLISEEDL), Flag epitope (DYKDDDDK, HA tag (YPYDVPDYA), 6 or 10 x His Tag, HSV (QPELAPEDPED), Pk-Tag (GKPIPNPLLGLDST), protein C (EDQVDPRLIDGK), T7 (MASMTGGQQMG), VSV-G (YTDIEMNRLGK), Fusion proteines may include Thioredoxin, Glutathiontransferase (GST), Maltose binding Protein (MBP), Cellulose Binding protein, calmodulin binding protein, chitin binding protein, ubiquitin, the Fc part of Immunoglobulins, and the IgG binding domain of Staphylococcus aureus protein A. These examples of course are illustrative and not limiting.

For expression of recombinant proteins in living cells or organisms, vector constructs harboring recombinant cofactor as set forth in SEQ ID NO. 1 and 3 are transformed or transfected into appropriate host cells. Preferably, a recombinant host cell of the present invention is transfected with a polynucleotide of SEQ ID NO. 1 and 3.

Means of transforming or transfecting cells with exogenous polynucleotide such as DNA molecules are well known in the art and include techniques such as calcium- phosphate-or DEAE-dextran-mediated transfection, protoplast fusion,

electroporation, liposome mediated transfection, direct microinjection and virus infection (Sambrook et al., 1989).

The most frequently applied technique for transformation of prokaryotic cells is transformation of bacterial cells after treatment with calciumchloride to increase permeability (Dagert & Ehrlich, 1979), but a variety of other methods is also available for one skilled in the art.

The most widely used method for transfection of eukaryotic cells is transfection mediated by either calcium phosphate or DEAE-dextran. Although the mechanism remains obscure, it is believed that the transfected DNA enters the cytoplasm of the cell by endocytosis and is transported to the nucleus. Depending on the cell type, up to 90% of a population of cultured cells may be transfected at any one time. Because of its high efficiency, transfection mediated by calcium phosphate or DEAE-dextran is the method of choice for studies requiring transient expression of the foreign nucleic acid in large numbers of cells. Calcium phosphate-mediated transfection is also used to establish cell lines that integrate copies of the foreign DNA, which are usually arranged in head-to-tail tandem arrays into the host cell genome.

In the protoplast fusion method, protoplasts derived from bacteria carrying high numbers of copies of a plasmid of interest are mixed directly with cultured mammalian cells. After fusion of the cell membranes (usually with polyethylene glycol), the contents of the bacterium are delivered into the cytoplasm of the mammalian cells and the plasmid DNA is transported to the nucleus. Protoplast fusion is not as efficient as transfection for many of the cell lines that are commonly used for transient expression assays, but it is useful for cell lines in which endocytosis of DNA occurs inefficiently. Protoplast fusion frequently yields multiple copies of the plasmid DNA tandemly integrated into the host chromosome.

The application of brief, high-voltage electric pulses to a variety of mammalian and plant cells leads to the formation of nanometer-sized pores in the plasma membrane.

DNA is taken directly into the cell cytoplasm either through these pores or as a consequence of the redistribution of membrane components that accompanies closure of the pores. Electroporation may be extremely efficient and may be used

both for transient expression of cloned genes and for establishment of cell lines that carry integrated copies of the gene of interest. Electroporation, in contrast to calcium phosphate-mediated transfection and protoplast fusion, frequently gives rise to cell lines that carry one, or at most a few, integrated copies of the foreign DNA.

Liposome transfection involves encapsulation of DNA and RNA within liposomes, followed by fusion of the liposomes with the cell membrane. The mechanism of how DNA is delivered into the cell is unclear but transfection efficiencies may be as high as 90%.

Direct microinjection of a DNA molecule into nuclei has the advantage of not exposing DNA to cellular compartments such as low-pH endosomes. Microinjection is therefore used primarily as a method to establish lines of cells that carry integrated copies of the DNA of interest.

The use of adenovirus as a vector for cell transfection is well known in the art.

Adenovirus vector-mediated cell transfection has been reported for various cells (Stratford-Perricaudet et al., 1992).

A transfected cell may be prokaryotic or eukaryotic, transfection may be transient or stable. Where it is of interest to produce a full length human or mammalian CF7 or CF8 protein, cultured mammalian or human cells are of particular interest.

In another aspect, the recombinant host cells of the present invention are prokaryotic host cells. In addition to prokaryotes, eukaryotic microbes, such as yeast may also be used illustrative examples for suitable cells and organisms for expression of recombinant proteins are belonging to but not limited to the following examples: Insect cells, such as Drosophila Sf21, SF9 cells or others, Expression strains of Escherichia coli, such as XL1 blue, BRL21, M15, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Hansenlua polymorpha and Pichia pastors strains, immortalized mammalian cell lines such as AtT-20, VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COSM6, COS-7,293 and MDCK cells, BHK-21 cells, Att 20HeLa cells, HeK 294, T47 D cells and others.

Expression of recombinant proteins within the scope of this invention can also be performed in vitro. This may occur by a two step procedure, thereby producing first mRNA by in vitro transcription of an apt polynucleotide construct followed by in vitro translation with convenient cellular extracts. These cellular extracts may be reticulocyte lysates but are not limited to this type. In vitro transcription may be performed by T7 or SP6 DNA polymerase or any other RNA polymerase which can recognize per se or with the help of accessory factors the promoter sequence contained in the recombinant DNA construct of choice. Alternatively one of the recently made available one step coupled transkription/translation systems may be used for in vitro translation of DNA coding for the proteins of this invention. One illustrative but not limiting example for such a system is the TNT (É) T7 Quick System by Promega.

Expression of recombinant proteins in transfected cells may occur constitutively or upon induction. Procedures depend on the Cell/vector combination used and are well known in the art. In all cases, transfected cells are maintained for a period of time sufficient for expression of the recombinant cofactor proteins according to the invention. A suitable maintenance time depends strongly on the cell type and organism used and is easily ascertainable by one skilled in the art. Typically, maintenance time is from about 2 hours to about 14 days. For the same reasons and for sake of protein stability and solubility incubation temperatures during maintenance time may vary from 20°C to 42 °C.

Recombinant proteins are recovered or collected either from the transfected cells or the medium in which those cells are cultured. Recovery comprises cell disruption, isolation and purification of the recombinant protein. Isolation and purification techniques for polypeptides are well-known in the art and include such procedures as precipitation, filtration, chromatography, electrophoresis and the like.

In a preferred embodiment, purification includes but is not limited to affinity purification of tagged or non-tagged recombinant proteins. This is a well established robust technique easily adapted to any tagged protein by one skilled in the art. For affinity purification of tagged proteins, small molecules such as gluthathione, maltose or chitin, specific proteins such as the IgG binding domain of Staphylococcus aureus

protein A, antibodies or specific chelate which bind with high affinity to the tag of the recombinant protein are employed. For affinity purification of non-tagged proteins specific monoclonal or polyclonal antibodies, which were raised against said protein, can be used. Alternatively, immobilized specific interactors of said protein may be employed for affinity purification. Interactors include native or recombinant proteins as well as native or artificial specific low molecular weight ligands.

CHEMICAL SYNTHESIS OF THE POLYPEPTIDE ACCORDING TO THE INVENTION : Alternatively, the protein itself may be produced using chemical methods to synthesize any of the amino acid sequences according to the invention (SEQ ID No: SEQ ID NO. 3 or 6) or that is encoded by the nucleotide sequences according to the invention (SEQ ID NO. 1 or 4) and/or a portion thereof. For example, peptide synthesis can be performed using conventional Merrifield solid phase f-Moc ort-Boc chemistry or various solid-phase techniques (Roberge, J. Y. et al. (1995) Science 269: 202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer). The newly synthesized peptide (s) may be substantially purified by preparative high performance liquid chromatography (e. g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, N. Y.). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e. g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequences according to the invention, i. e. SEQ ID NO. 3 or 6 or the sequence that is encoded by SEQ ID NO. 1 or 4 or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

COMPLEXES OF THE COFACTOR ACCORDING TO THE INVENTION WITH OTHER POLYPETIDES As outlined above CF7 and CF8 binds a nuclear receptor in vivo either directly or through another protein. In a preferred embodiment of the invention CF7 or CF8 are

complexed with a nuclear receptor. Such complexes are particular suited for all forms of binding or screening assays (see also below). Thus, in a preferred embodiment of the invention such assays are performed with complexes of a nuclear receptor associated with CF7 or CF8.

Such a complex may additionally comprise other protein or non-protein cofactors.

Such heterotrimers may be used in binding and screening assays as outlined below.

In one embodiment of the invention the entire CF7 or CF8 polypeptide is part of the complex but only a portion, e. g. a truncated fragment of the other polypeptide is part of the complex.

SCREENING ASSAYS In still a further embodiment, the present invention concerns a method for identifying new inhibitory or stimulatory substances of the cofactor according to the invention, these substances may be termed as"candidate substances". It is contemplated that this screening technique proves useful in the general identification of compounds that serve the purpose of inhibiting or stimulating cofactor activity.

In one embodiment of the invention the following substances are disclosed as potential interactors of such a nuclear receptor CF7 or CF8 cofactor complex as outlined above: Steroids: dexamethasone-t-butylacetate, RU486, progesterone, 17-alpha- hydroxyprogesterone, 1,16-alpha dimethylpregnenolone, 17-alpha- hydroxypregnenonlone, pregnenonlone, 5beta-pregnane-3,20-dione, pregnenonlone- 16-carbonitrile, 5beta-pregnane-3,20-dione, androstanol, corticosterone, dehydroepiandrosterone, dihydroxytestosterone, estradiol, cortisol, cortisone, dihydroxytestosterone.

Other substances: transnonachlor, chlordane, spironolactone, cyproterone acetate, rifampicin, nefipine, diethylstilbestrol, coumesterol, clotrimazole, lovastatin, phenoarbital, pthalic acid, nonylphenol, 1,4-bis (2- (3, 5-dichloropyridyloxy1)) benzene,

This also includes the use of heteromultimeric complexes of the cofactor protein with other proteins.

Accordingly, in screening assays to identify pharmaceuticals agents which affect cofactor activity, it is proposed that compounds isolated from natural sources, such as fungal extracts, plant extracts, bacterial extracts, higher eukaryotic cell extracts, or even extracts from animal sources, or marine, forest or soil samples, may be assayed for the presence of potentially useful pharmaceutical agents.

It will be understood that that the pharmaceutical agents to be screened can also be derived from chemical compositions or man-made compounds. The candidate substances can could also include monoclonal or polyclonal antibodies, peptides or proteins, such as those derived from recombinant DNA technology or by other means, including chemical peptide synthesis. The active compounds may include fragments or parts or derivatives of naturally-occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive. We anticipate that such screens will in some cases lead to the isolation of agonists of nuclear receptors or cofactors, in other cases to the isolation of antagonists. In other instances, substances will be identified that have mixed agonistic and antagonistic effects, or affect nuclear receptors or cofactors in any other way.

In another embodiment, the invention concerns the isolation of substance inhibiting the interaction of the cofactor protein and the nuclear receptor. Such substances are useful for the development of drugs against diseases such as infertility. Substances disrupting the interactions may be isolated by a variety of screening methods including the two hybrid system or the reverse two hybrid system (Lenna C. A. and Hannink, M. 1996, Nucl. Acids Res. 24: 3341-3347), or any variation of cellular or cell free assays as described in this invention, as is obvious to anyone skilled in the art.

In an important embodiment of the invention, the binding of the cofactor protein and the nuclear receptor can be used to monitor the binding of a substance to one of the binding partners. The substance, which can be a small molecule such as a ligand to a nuclear receptor, will lead to a change in the allosteric conformation of the binding

protein which in consequence leads to a loss of the interaction of the two proteins.

Using this effect of ligand-dependent protein-protein interactions one can design assays where the protein-protein interaction serves as a surrogate read-out for the binding of one of the proteins to small molecule ligand. Any assay method which is useful for the measurement of protein-protein interactions can be used for such an indirect assay. Such assay methods are well known in the art and include the methods described in this patent under"Cell free assays"and"Cell based assays".

CELL BASED ASSAYS To identify a candidate substance capable of influencing the cofactor protein activity, one first obtains a recombinant cell line. One designs the cell line in such a way that the activity of the cofactor leads to the expression of a protein which has an easily detectable phenotype (a reporter), such as luciferase, fluorescent proteins such as green or red fluorescent protein, beta-galactosidase, alpha-galactosidase, beta- lactamase, chloramphenicol-acetyl-transferase, beta-glucuronidase, or any protein which can be detected by a secondary reagent such as an antibody.

Methods for detecting proteins using antibodies, such as ELISA assays, are well known to those skilled in the art.

Here, the amount of reporter protein present reflects the activity of the cofactor. This recombinant cell line is then screened for the effect of substances on the expression of the reporters, thus measuring the effect of these substances on the activity of the cofactor. These substances can be derived from natural sources, such as fungal extracts, plant extracts, bacterial extracts, higher eukaryotic cell extracts, or even extracts from animal sources, or marine, forest or soil samples, may be assayed for the presence of potentially useful pharmaceutical agents. It will be understood that that the pharmaceutical agents to be screened may be derived from chemical compositions or man-made compounds.

The candidate substances can also include monoclonal or polyclonal antibodies, peptides or proteins, such as those derived from recombinant DNA technology or by other means, including chemical peptide synthesis. The active compounds may

include fragments or parts or derivatives of naturally-occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive.

In general the assay can be performed by firstly bringing a suitable cell containing a reporter gene which transcription is influenced by the cofactor activity in contact with a compound and secondly monitoring the expression of the reporter gene to evaluate the effect of the compound on the activity of the cofactor (CF7 or CF8).

In other embodiments of the invention assays are included where measuring the activity of di-or multimeric complexes of the cofactor and other proteins. Further included are assays aiming at the identification of compounds which specifically influence only the monomeric, homodimeric or homomultimeric form of the cofactor, or influencing only multimeric forms of the cofactor. Such assays include measuring the effect of a compound on the cofactor in the absence of a binding partner, and measuring the effect of a compound on the cofactor in the presence of a binding partner. One skilled in the art will find numerous more assays which are equally covered by the invention.

A cell line where the activity of the nuclear receptor bound by the cofactor according to the invention determines the expression of a reporter can be obtained by generating an artificial promoter upstream of the reporter gene, which contains preferably multiple copies of HREs to which the nuclear receptor binds.

Furthermore, transgenic animals described in the invention can be used to derive cell lines useful for cellular screening assays.

Cell lines useful for such an assay include many different kinds of cells, including prokaryotic, animal, fungal, plant and human cells. Yeast cells can be used in this assay, including Saccharomyces cerevisiae and Schizosaccharomyces pombe cells.

One way of building cellular assays is by measuring the effect of compounds is the use of the two hybrid system (see for example see, for example, U. S. Pat. No.

5,283,317; Zervos et al. (1993) Cell 72: 223-232; Madura et al. (1993) J. Biol. Chem.

268: 12046-12054; Bartel et al. (1993) Biotechniques 14: 920-924 ; Iwabuchi et al.

(1993) Oncogene 8: 1693-1696; PCT Publication No. WO 94/10300, and U. S. Pat.

No. 5,667,973), or possible variants of the basic two hybrid system as discussed e. g. in Vidal M, Legrain P, Nucleic Acids Res 1999 Feb 15; 27 (4): 919-29. Briefly, the two hybrid assay relies on reconstituting in vivo a functional transcriptional activator protein from two separate fusion proteins. In particular, the method makes use of chimeric genes which express hybrid proteins. To illustrate, a first hybrid gene comprises the coding sequence for a DNA-binding domain of a transcriptional activator fused in frame to the coding sequence for a cofactor. The second hybrid protein encodes a transcriptional activation domain fused in frame to another gene, for example the nuclear receptor protein PPAR gamma. If the cofactor and PPAR gamma proteins are able to interact, they bring into close proximity the two domains of the transcriptional activator. This proximity is sufficient to cause transcription of a reporter gene which is operably linked to a transcriptional regulatory site responsive to the transcriptional activator, and expression of the reporter gene can be detected and used to score for the interaction of the cofactor and PPAR gamma proteins.

Suitable host cells for such assays include yeast cells, but also mammalian cells or bacterial cells.

In such assays, one primarily measures the effect of a compound on a given interaction involving the CF7 or CF8 cofactors and a binding protein. In a preferred embodiment of the invention systems using other hosts such as prokaryotes as E. coli, or eukaryotic mammalian cells are described.

Two hybrid systems using hybrid protein fusions with other proteins than transcription factors, including enzymes such as beta-galactosidase or dihydrofolate reductase may also be applied. These assays are useful both to monitor the effect of a compound, including peptides, proteins or nucleic acids on an interaction of a cofactor with a given binding partner, as well. as to identify novel proteins or nucleic acids interacting with the cofactor.

CELL-FREE ASSAYS

Recombinant forms of the polypeptides according to SEQ ID NO. 3 and 6 can be used in cell-free screening assays aiming at the isolation of compounds affecting the activity of cofactors. In such an assay, the cofactor polypeptides are brought into contact with a substance to test if the substance has an effect on the activity of the cofactor.

The detection of an interaction between an agent and a cofactor may be accomplished through techniques well-known in the art. These techniques include but are not limited to centrifugation, chromatography, electrophoresis and spectroscopy. The use of isotopically labeled reagents in conjunction with these techniques or alone is also contemplated. Commonly used radioactive isotopes include 3H 14C 22Na 32p 33p 3SS 45Ca 60Co, 1251, and 1311 commonlY used stable isotopes include. H,. C, N, 0.

For example, if an agent binds to any of the cofactors of the present invention, the binding may be detected by using radiolabeled agent or radiolabeled cofactor. Briefly, if radiolabeled agent or radiolabeled cofactor is utilized, the agent-cofactor complex may be detected by liquid scintillation or by exposure to x-ray film or phosho-imaging devices.

One way to screen for substances affecting cofactor activity is to measure the effect of the substance on the binding affinity of the cofactor to other proteins or molecules, such as activators or repressors, DNA, RNA, other proteins, antibodies peptides or other substances, including chemical compounds known to affect cofactor activity.

Assays measuring the binding of a protein to a ligand are well known in the art, such as ELISA assays, FRET assays, bandshift assays, plasmon-resonance based assays, scintilllation proximity assays, fluorescence polarization assays, alpha screen assays.

In one example, a mixture containing a cofactor polypeptide, effector and candidate substance is allowed to incubate. The unbound effector is separable from any effector/cofactor complex so formed. One then simply measures the amount of each (e. g., versus a control to which no candidate substance has been added). This measurement may be made at various time points where velocity data is desired.

From this, one determines the ability of the candidate substance to alter or modify the function of the cofactor.

Numerous techniques are known for separating the effector from effector/cofactor complex, and all such methods are intended to fall within the scope of the invention.

This includes the use of thin layer chromatographic methods (TLC), HPLC, spectrophotometric, gas chromatographic/mass spectrophotometric or NMR analyses. Another method of separation is to immobilize one of the binding partners on a solid support, and to wash away any unbound material. It is contemplated that any such technique may be employed so long as it is capable of differentiating between the effector and complex, and may be used to determine enzymatic function such as by identifying or quantifying the substrate and product.

A screening assay in which candidate agent binding of cofactors is analysed can include a number of conditions. These conditions include but are not limited to pH, temperature, tonicity, the presence of relevant other proteins, and relevant modifications to the polypeptide such as glycosylation or lipidation. It is contemplated that the cofactors can be expressed and utilized in a prokaryotic or eukaryotic cell.

The host cell expressing the cofactors can be used whole or the cofactor can be isolated from the host cell. The cofactor can be membrane bound in the membrane of the host cell or it can be free in the cytosol of the host cell. The host cell can also be fractionated into sub-cellular fractions where the cofactor can be found. For example, cells expressing the cofactor can be fractionated into the nuclei, the endoplasmic reticulum, vesicles, or the membrane surfaces of the cell. pH is preferably from about a value of 6.0 to a value of about 8. 0, more preferably from about a value of about 6.8 to a value of about 7.8, and most preferably, about 7.4. In a preferred embodiment, temperature is from about 20°C degrees to about 50°C degrees more preferably, from about 30°C degrees to about 40°C degrees and even more preferably about 37°C degrees. Osmolality is preferably from about 5 milliosmols per liter (mosm/L) to about 400 mosm/l, and more preferably, from about 200 milliosmols per liter to about 400 mosm/) and, even more preferably from about 290 mosm/L to about 310 mosm/L. The presence of further cofactors or other proteins can be required for the proper functioning of the cofactor according to the

invention. Typical chemical compounds known as prosthetic groups include sodium, potassium, calcium, magnesium, and chloride. In addition, small, non-peptide molecules may also be required. Other biological conditions needed for cofactor function are well-known in the art.

It is well-known in the art that proteins can be reconstituted in artificial membranes, vesicles or liposoms. (Danboldt et al., 1990). The present invention contemplates that the cofactor can be incorporated into artificial membranes, vesicles or liposoms.

The reconstituted cofactor can be utilized in screening assays.

It is further contemplated that the cofactor CF7 and/or CF8 of the present invention can be coupled to a solid support, e. g., to agarose beads, polyacrylamide beads, polyacrylic, sepharose beads or other solid matrices capable of being coupled to polypeptides. Well-known coupling agents include cyanogen bromide (CNBr), carbonyldiimidazole, tosyl chloride, diaminopimelimidate, and glutaraldehyde.

In a typical screening assay for identifying candidate substances, one employs the same recombinant expression host as the starting source for obtaining the cofactor polypeptide, generally prepared in the form of a crude homogenate. Recombinant cells expressing the cofactor are washed and homogenized to prepare a crude polypeptide homogenate in a desirable buffer such as disclosed herein, In a typical assay, an amount of polypeptide from the cell homogenate, is placed into a small volume of an appropriate assay buffer at an appropriate pH. Candidate substances, such as agonists and antagonists, are added to the admixture in convenient concentrations and the interaction between the candidate substance and the cofactor polypeptide is monitored.

Where one uses an appropriate known substrate for the cofactor, one can, in the foregoing manner, obtain a baseline activity for the recombinantly produced cofactor.

Then, to test for inhibitors or modifiers of the cofactor function, one can incorporate into the admixture a candidate substance whose effect on the cofactor is unknown.

By comparing reactions which are carried out in the presence or absence of the candidate substance, one can then obtain information regarding the effect of the candidate substance on the normal function of the cofactor.

Accordingly, this aspect of the present invention will provide those of skill in the art with methodology that allows for the identification of candidate substances having the ability to modify the action of the cofactor polypeptide in one or more manners.

Additionally, screening assays for the testing of candidate substances are designed to allow the determination of structure-activity relationships of agonists or antagonists with the cofactor, e. g., comparisons of binding between naturally-occurring hormones or other substances capable of interacting with or otherwise modulating nuclear receptor and/or the cofactor; or comparison of the activity caused by the binding of such molecules to the cofactor.

In certain aspects, the polypeptides of the invention are crystallized in order to carry out x-ray crystallographic studies as a means of evaluating interactions with candidate substances or other molecules with the cofactor polypeptide. For instance, the purified recombinant polypeptides of the invention, i. e. of the cofactors according to the invention, when crystallized in a suitable form, are amenable to detection of intra-molecular interactions by x-ray crystallography. In another aspect, the structure of the polypeptides can be determined using nuclear magnetic resonance.

PHARMACEUTICAL COMPOSITION : This invention provides a pharmaceutical composition comprising an effective amount of an agonist or antagonist drug identified by the method described herein and a pharmaceutical acceptable carrier. Such drugs and carrier can be administered by various routes, for example oral, subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of about 0.01-100 mg/kg.

This invention provides a method of treating metabolic disorders, immunological indications, hormonal dysfunctions, neurosystemic diseases, wherein the abnormality is improved by altering the activity of the cofactor thereby influencing the binding affinity of the cofactor to the nuclear receptor. Similarly, the invention also provides methods for treating diseases and conditions resulting from metabolic disorders,

immunological indications, hormonal dysfunctions, neurosystemic diseases, or other diseases which method comprises administering an effective amount of an agonist- or antagonist containing pharmaceutical composition described above.

TRANSFORMATION OF CELLS AND DRUG SCREENING : The recombinant expression constructs of the present invention are useful in molecular biology to transform cells which do not ordinarily express CF7 or CF8 to express these cofactors upon transformation.

Such cells are useful as intermediates for making cellular preparations useful for cofactor binding assays, which are in turn useful for drug screening.

The recombinant expression constructs of the present invention are also useful in gene therapy. Cloned genes of the present invention, or fragments thereof, may also be used in gene therapy carried out by homologous recombination or site-directed mutagenesis. See generally Thomas & Capecchi, Cell 51,503-512 (1987); Bertling, Bioscience Reports 7,107-112 (1987) ; Smithies et al., Nature 317,230-234 (1985).

Oligonucleotides of the present invention are useful as diagnostic tools for probing cofactor gene expression in tissues. For example, tissues are probed in situ with oligonucleotide probes carrying detectable groups by conventional autoradiographic techniques, as explained in greater detail in the Examples below, to investigate native expression of this cofactor or pathological conditions relating thereto. Further, chromosomes can be probed to investigate the presence or absence of the CF7 and/or CF8 gene, and potential pathological conditions related thereto, as also illustrated by the examples below. Probes according to the invention should generally be at least about 15 nucleotides in length to prevent binding to random sequences, but, under the appropriate circumstances may be smaller.

ANTIBODIES AGAINST THE CF7 AND/OR CF8 COFACTOR PROTEIN OR POLYPEPTIDE

Another aspect of the invention includes antibodies specifically reactive with the proteins or any parts of the proteins according to the invention (SEQ ID NO. 3 or 6) and or polypeptides encoded by the nucleotide sequence of the cofactor or its complement (SEQ ID NO. 1 or SEQ ID NO. 4). (The term, antibody" refers to intact molecules as well as fragments thereof, such as Fa, F (ab). sub. 2, and Fv, which are capable of binding the epitopic determinant.) By using immunogens derived from the polypeptide according to the invention and/or encoded by the nucleic acid according to the invention, anti-protein/anti-peptide antiserum or monoclonal antibodies can be made by standard protocols (E. Howell & D. Lane. Antibodies: A Laboratory Manual.

Cold Spring Harbor Laboratory (1988)).

A polyclonal antibody is prepared by immunizing a mammal, such as a mouse, a hamster or rabbit with an immunogenic form of the cofactor according to the invention depending on which of these are desired of the present invention, and collecting antisera from that immunized animal. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

As an immunizing antigen, fusion proteins, intact polypeptides or fragments containing small peptides of interest can be used. They can be derived by expression from a cDNA transfected in a host cell with subsequent recovering of the protein/peptide or peptides can be synthesized chemically (e. g. oligopeptides with 10-15 residues in length). Important tools for monitoring the function of the cofactor gene according to the present invention, i. e. encoded by a sequence according to SEQ ID NO. 1 or 4 are antibodies against various domains of the proteins according to the invention.

A given polypeptide or polynucleotide may vary in its immunogenicity. It is often necessary to couple the immunogen (e. g. the polypeptide) with a carrier. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal in the presence of an adjuvant, a non-specific stimulator of the immune response in order to enhance immunogenicity. The production of polyclonal antibodies is monitored by detection of antibody titers in plasma or serum at various

time points following immunization. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies. When a desired level of immunogenicity is obtained, the immunized animal may be bled and the serum isolated, stored and purified.

To produce monoclonal antibodies, antibody-producing cells (e. g. spleen cells) from an immunized animal (preferably mouse or rat) are fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Where the immunized animal is a mouse, a preferred myeloma cell is the murine NS-1 myeloma cell. Such techniques are well known in the art, and include, for example, the hybridoma technique (originally developed by Kohler & Milstein.

Nature 256: 495-497 (1975)), the human B cell hybridoma technique (Kozbar et aL Immunology Today 4: 72 (1983)), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et aL Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, Inc. pp. 77-96 (1985)).

The fused spleen/myeloma cells are cultured in a selective medium to select fused spleen/myeloma cells from the parental cells. Fused cells are separated from the mixture of non-fused parental cells, for example, by the addition of agents that block the de novo synthesis of nucleotides in the tissue culture media. This culturing provides a population of hybridomas from which specific hybridomas are selected.

Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants for reactivity with an antigen-polypeptide. The selected clones may then be propagated indefinitely to provide the monoclonal antibody in convenient quantity.

The creation of antibodies which specifically bind the polypeptide according to the invention and/or encoded by the nucleotide sequence of the cofactor or its complements provides an important utility in immunolocalization studies, and may play an important role in the diagnosis and treatment of such diseases and disorders as metabolic disorders, immunological indications, hormonal dysfunctions and/or neurosystemic diseases. The antibodies may be employed to identify tissues, organs, and cells which express the cofactor. Antibodies can be used diagnostically

in immuno-precipitation and immuno-blotting to detect and evaluate cofactor protein levels in tissue or from cells in bodily fluid as part of a clinical testing procedure.

Monoclonal antibodies provided by the present invention are also produced by recombinant genetic methods well known to those of skill in the art, and the present invention encompasses antibodies made by such methods that are immunologically reactive with an epitope of a mammalian cofactor protein or peptide according to the invention.

The present invention encompasses fragments of the antibody that are immunologically reactive with an epitope of a cofactor protein or peptide. Such fragments are produced by any number of methods, including but not limited to proteolytic cleavage, chemical synthesis or preparation of such fragments by means of genetic engineering technology. The present invention also encompasses single- chain antibodies that are immunologically reactive with an epitope of a cofactor protein or peptide made by methods known to those of skill in the art.

CHIMERIC ANTIBODIES AND OTHER TYPES OF ANTIBODIES : The invention also includes chimeric antibodies, comprised of light chain and heavy chain peptides immunologically reactive to an epitope that is a cofactor protein or peptide according to the invention. The chimeric antibodies embodied in the present invention include those that are derived from naturally occurring antibodies as well as chimeric antibodies made by means of genetic engineering technology well known to those of skill in the art.

Also included are methods for the generation of antibodies against any of the group comprising the peptides according to SEQ ID NO. 3 and SEQ ID NO. 6 which rely on the use of phage display systems and related systems, such as described in Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC, Immunotechnology 1998 Jun; 4 (1) : 1-20, and references therein.

EPITOPES OF THE CF7 AND/OR CF8 COFACTORS The present invention also encompasses one or more epitopes of a cofactor protein or peptide that is comprised of sequences and/or a conformation of sequences present in the cofactor proteins or peptide molecule. These epitopes may be naturally occurring, or may be the result of proteolytic cleavage of the cofactor protein or peptides and isolation of an epitope-containing peptide or may be obtained by synthesis of an epitope-containing peptide using a method of genetic engineering technology and synthesized by genetically engineered prokaryotic or eukaryotic cells.

ANTISENSE OLIGONUCLEOTIDES AGAINST CF7 AND/OR CF8 GENE TRANSCRIPTS Antisense oligonucleotides are short single stranded DNA or RNA molecules which may be used to block the availability of the cofactor messenger (s). Synthetic derivatives of ribonucleotides or desoxyribonucleotides and/or PNAs (see above) are equally possible. These are potential candidate agents which may interact with the cofactor according to the invention.

The sequence of an antisense oligonucleotide is at least partially complementary to the sequence of the CF7 or CF8 cofactor. The complementarity of the sequence is in any case high enough to enable the antisense oligonucleotide to bind to the nucleic acid according to the invention or parts thereof (SEQ ID NO. 1 or 4) in which the binding of oligonucleotides to the target sequence interfere with the biological function of the targeted sequence (Brysch W, Schlingensiepen KH, Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents, Cell Mol Neurobiol 1994 Oct; 14 (5): 557-68; Wagner RW, Gene inhibition using antisense oligodeoxynucleotides, Nature 1994 Nov 24; 372 (6504): 333-5 or Brysch W, Magal E, Louis JC, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen KH Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation, Cancer Gene Ther 1994 Jun; 1 (2): 99-105 or Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF,

Freier SM Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides, J Biol Chem 1992 Oct 5; 267 (28): 19954-62 or Bertram J, Palfner K, Killian M, Brysch W, Schlingensiepen KH, Hiddemann W, Kneba M, Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes, Anticancer Drugs 1995 Feb; 6 (1) : 124-34) This interference occurs in most instances at the level of translation, i. e. through the inhibition of the translational machinery by oligonucleotides that bind to mRNA, however, two other mechanisms of interference with a given gene's function by oligonucleotides can also be envisioned, (i) the functional interference with the transcription of a gene through formation of a triple helix at the level of genomic DNA and the interference of oligonucleotides with the function of RNA molecules that are executing at least part of their biological function in the untranslated form (Kochetkova M, Shannon MF, Triplex-forming oligonucleotides and their use in the analysis of gene transcription. Methods Mol Biol 2000 ; 130: 189-201 Rainer B. Lanz1, Neil J. McKenna1, Sergio A. Onate1, Urs Albrecht2, Jiemin Wong1, Sophia Y. Tsai1, Ming-Jer Tsai1, and Bert W. O'Malley A Steroid Receptor Coactivator, SRA, Functions as an RNA and Is Present in an SRC-1 Complex Cell, Vol. 97,17-27, April, 1999).

Antisense oligonucleotides can be conjugated to different other molecules in order to deliver them to the cell or tissue expressing the cofactor gene, CF7 or CF8. For instance the antisense oligonucleotide can be conjugated to a carrier protein (e. g. ferritin) in order to direct the oligonucleotide towards the desired target tissue, i. e. in case of ferritin predominantly to the liver.

Antisense expression constructs are expression vector systems that allow the expression-either inducible or uninducible-of a complementary sequence to the cofactor sequences according to the invention. The potential possibility of such an approach has been demonstrated in many different model systems (von Ruden T, Gilboa E, Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA, J Virol 1989 Feb; 63 (2): 677-82; Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB, Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and

lactation deficiency, J Biol Chem 2000 Jan 14; 275 (2): 969-76; Ma L, Gauville C, Berthois Y, Millot G, Johnson GR, Calvo F Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line, Oncogene 1999 Nov 11; 18 (47): 6513-20; Refolo LM, Eckman C, Prada CM, Yager D, Sambamurti K, Mehta N, Hardy J, Younkin SG, Antisense-induced reduction of presenilin 1 expression selectively increases the production of amyloid beta42 in transfected cells, J Neurochem 1999 Dec; 73 (6): 2383-8; Buckley NJ, Abogadie FC, Brown DA, Dayrell M, Caulfield MP, Delmas P, Haley JE, Use of antisense expression plasmids to attenuate G-protein expression in primary neurons, Methods Enzymol 2000 ; 314: 136-48).

According to the invention an antisense expression construct can be constructed with virtually any expression vector capable of fulfilling at least the basic requirements known to those skilled in the art.

In one embodiment of the invention retroviral expression systems or tissue specific gene expression systems are preferred.

Current standard technologies for delivering antisense constructs are performed through a conjugation of constructs with liposomes and related, complex-forming compounds, which are transferred via electroporation techniques or via particle- mediated"gene gun"technologies into the cell. Other techniques may be envisioned by one skilled in the art.

Microinjection still plays a major role in most gene transfer techniques for the generation of germ-line mutants expressing foreign DNA (including antisense RNA constructs) and is preferred embodiment of the present invention.

RIBOZYMES DIRECTED AT CF7 AND/OR CF8 GENE TRANSCRIPT.

Ribozymes are either RNA molecules (Gibson SA, Pellenz C, Hutchison RE, Davey FR, Shillitoe EJ, Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector, Clin Cancer Res 2000 Jan; 6 (1) : 213-22; Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N, Inhibition of Telomerase

Activity by a Hammerhead Ribozyme Targeting the RNA Component of Telomerase in Human Melanoma Cells, J Invest Dermatol 2000 Feb; 114 (2): 259-267; Halatsch ME, Schmidt U, Botefur IC, Holland JF, Ohnuma T, Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA, J Neurosurg 2000 Feb; 92 (2): 297-305; Ohmichi T, Kool ET, The virtues of self-binding : high sequence specificity for RNA cleavage by self-processed hammerhead ribozymes, Nucleic Acids Res 2000 Feb 1; 28 (3): 776-783) or DNA molecules (Li J, Zheng W, Kwon AH, Lu Y, In vitro selection and characterization of a highly efficient Zn (Il)-dependent RNA-cleaving deoxyribozyme; Nucleic Acids Res 2000 Jan 15; 28 (2): 481-488) that have catalytic activity. The catalytic activity located in one part of the RNA (or DNA) molecule can be"targeted"to a specific sequence of interest by fusing the enzymatically active RNA molecule sequence with a short stretch of RNA (or DNA) sequence that is complementary to the cofactor gene transcript of interest.

Such a construct will, when introduced into a cell either physically or via gene transfer of a ribozyme expression construct find the corresponding cofactor sequence (our sequence of interest or also targeted in RNA) and bind via its sequence-specific part to said sequence. The catalytic activity attached to the construct, usually associated with a special nucleic acid structure (people distinguish so called "hammerhead"structures and"hairpin"structures), will then cleave the targeted RNA.

The targeted mRNA will be destroyed and cannot be translated efficiently, thus the protein encoded by the mRNA derived from cofactor will not be expressed or at least will be expressed at significantly reduced amounts.

These are potential candidate agents which may interact with the CF7 and/or CF8 cofactor according to the invention.

In a preferred embodiment the invention covers inducible ribozyme constructs (Koizumi M, Soukup GA, Kerr JN, Breaker RR, Allosteric selection of ribozymes that respond to the second messengers cGMP and cAMP, Nat Struct Biot 1999 Nov; 6 (11): 1062-1071).

In a further preferred embodiment the invention concerns the use of"bivalent" ribozymes (multimers of catalytically active nucleic acids) as described in (Hamada

M, Kuwabara T, Warashina M, Nakayama A, Taira K, Specificity of novel allosterically trans-and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression FEBS Lett 1999 Nov 12; 461 (1-2): 77-85).

TRANSGENIC ANIMALS CARRYING THE CF7 AND/OR CF8 COFACTOR GENE Also provided by the present invention are non-human transgenic animals grown from germ cells transformed with a CF7 or CF8 nucleic acid sequence according to the invention and that express the cofactor according to the invention and offspring and descendants thereof. Also provided are transgenic non-human mammals comprising a homologous recombination knockout of the native cofactors, as well as transgenic non-human mammals grown from germ cells transformed with nucleic acid antisense to the nucleic acids of the invention and offspring and descendants thereof. Further included as part of the present invention are non-human transgenic animals in which the native cofactor has been replaced with the human ortholog. Of course, offspring and descendants of all of the foregoing transgenic animals are also encompassed by the invention.

Transgenic animals according to the invention can be made using well known techniques with the nucleic acids disclosed herein. E. g., Leder et al., U. S. Patent Nos. 4,736,866 and 5,175,383; Hogan et al., Manipulating the Mouse Embryo, A Laboratory Manual (Cold Spring Harbor Laboratory (1986)); Capecchi, Science 244, 1288 (1989); Zimmer and Gruss, Nature 338,150 (1989); Kuhn et al., Science 269, 1427 (1995); Katsuki et al., Science 241,593 (1988); Hasty et al., Nature 350,243 (1991); Stacey et al., Mol. Cell Biol. 14,1009 (1994); Hanks et al., Science 269,679 (1995); and Marx, Science 269,636 (1995). Such transgenic animals are useful for screening for and determining the physiological effects of the cofactor agonists and antagonist.

Consequently, such transgenic animals are useful for developing drugs to regulate physiological activities in which the CF7 or CF8 cofactor participates.

MODELLING OF THE STRUCTURE OF CF7 AND CF8.

In one embodiment of the invention the amino acid sequences of the present invention can be used for structural drug design. The aim is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact (e. g. agonists, antagonists or inhibitors) in order to design drugs which are, for example, more active or stable forms of the polypeptide, or which, for example, enhance or interfere with the function of a polypeptide in vivo. In one approach one first determines the three-dimensional structure of a protein of interest, i. e. the cofactor, by computer-modeling, x-ray crystallography or a combination of both approaches. Additional, useful information with respect to the structure of a polypeptide could also be gained from comparison of the protein sequence of the protein of interest with the sequence of related proteins where the structure is known.

From the three-dimensional structure, binding sites of potential inhibitors or activators can be predicted. It can further be predicted which kinds of molecule might bind there. The predicted substances can then be screened to test their effect on the activity of the protein and its biological function.

EXAMPLES EXAMPLE 1: CLONING AND EXPRESSION OF THE CF7 AND CF8 GENE ACCORDING TO THE INVENTION PCR may be used to amplify a single open reading frame of CF7, e. g. using CF7 Primer 1 5'atggcagctg aagaaattaa tg 3' (SEQ ID NO. 7) and CF7 Primer 25'ttaactttta ctttttcc3' (SEQ ID NO. 8) (see also Fig. 1 for the primers for CF8). The PCR product is purified and cloned into a suitable vector.

Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques that are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and related in the form desired.

Site-specific DNA cleavage is performed by treatment with the suitable restriction enzyme (or enzymes) under conditions that are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes.

See, e. g., New England Biolabs, Product Catalog. In general, about 1 lug of plasmid and/or DNA sequence is cleaved by one unit of enzyme in about 20 NI of buffer solution. Often excess of restriction enzyme is used to ensure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37°C are workable, although variations are tolerable.

After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction. The nucleic acid may be recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology 65,499-560 (1980).

Transformed host cells are cells which have been transformed or transfected with recombinant expression constructs made using recombinant DNA techniques and comprising cofactor encoding sequences. Preferred host cells for transient transfection are COS-7 cells. Transformed host cells may ordinarily express the cofactor but host cells transformed for purposes of cloning or amplifying nucleic acid hybridization probe DNA need not express the cofactors. When expressed, the cofactor protein will typically be located in the host cell membrane.

Cultures of cells derived from multicellular organisms are desirable hosts for recombinant nuclear receptor protein synthesis. In principal, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. However, mammalian cells are preferred. Propagation of such cells in cell culture has become a routine procedure. See Tissue Culture (Academic Press, Kruse & Patterson, Eds., 1973). Examples of useful host cell lines are bacteria cells, insect cells, yeast cells,

human 293 cells, VERO and HeLa cells, LMTK-cells, and W ! 138, BHK, COS-7, CV, and MDCK cell lines. Human 293 cells are preferred.

EXAMPLE 2: COFACTOR CF7 AND/OR CF8 TISSUE LOCALIZATION : A multiple tissue northern blot (Clontech, Palo Alto) is hybridized to a labeled probe.

The blot contains about 0.3 to 3 ug of poly A RNA derived from various tissues, preferentially including tissue from testis and preferentially or male origin.

Hybridization may be carried out in a hybridization solution such as one containing SSC (see Maniatis et al, ibid) at an optimized temperature between 50°c and 70°C, preferably 65°C. The filter may be washed and a film exposed for signal detection (see also : Maniatis et al., Molecular Cloning : A laboratory Manual, Cold Spring Harbor Laboratory Press, N. Y. (1989)).

EXAMPLE 3: COFACTOR cDNA ISOLATION FROM HUMAN AND OTHER ORGANISMS : A cloning strategy is used to clone the CF7 or CF8 cofactor cDNA from specific cDNA libraries (Clontech, Palo Alto) or alternatively, RNA is obtained from various tissues and used to prepare cDNA expression libraries by using for example an Invitrogen kit. (Invitrogen Corporation, San Diego). For the isolation of the CF7 or CF8 cDNA clones the chosen library may be screened under stringent condition (see definitions above) by using CF7 or CF8 specific probes, in general such probes consist of fragments of DNA from within the CF7 gene, generated by PCR, using CF7 or CF8 specific primers (e. g. Primer 1 and 2 of Figure 1). After identification of positives, the cDNA insert of positive clones is subsequently sequenced and cloned in a suitable expression vector.

Additionally, full length cofactor clones from various species are obtained by using RACE PCR technology. In brief, suitable cDNA libraries are constructed or purchased. Following reverse transcription, the first strand cDNA is used directly in RACE PCR reactions using a RACE cDNA amplification kit according to the

manufactures protocol (Clontech, Palo Alto). Amplified fragments are purified, cloned and subsequently used for sequence analysis.

To obtain information about the genomic organization of the cofactor gene, genomic libraries (Clontech, Palo Alto) are screened with a receptor specific probe under stringent conditions. Positive clones are isolated and the complete DNA sequence of the receptor cofactor is determined by sequence analysis (Maniatis et al., Molecular Cloning : A laboratory Manual, Cold Spring Harbor Laboratory Press, N. Y. (1989)).

EXAMPLE 4: ISOLATION OF THE NUCLEAR RECEPTOR BINDING PARTNER OF THE COFACTOR PROTEIN BY USE OF THE YEAST TWO-HYBRID SYSTEM A yeast two-hybrid assay is performed using methods such as described by Fields and Song Nature 340, pp245 (1989), Bartel et al., Biotechniques 14, pp920 (1993) and Lee et al. Nature 374 pp91-4 (1995). A sequence encoding amino acids according to SEQ ID NO. 3 of CF7 or SEQ ID NO. 6 of CF8 is cloned into the vector pGBT9 (Clontech) in such way that, after transformation of the haploid yeast strain CG1945 (Clontech), a hybrid protein is expressed consisting of the DNA-binding domain (BD) of the Gal4 transcription factor fused N-terminally to all amino acids according to SEQ ID NO. 3 or parts thereof.. CG1945 cells expressing the Gal4BD :: PXR fusion protein are mated to cells of strain Y187 (Clontech) containing a library of Gal4 transcription activation domain (AD) fusion plasmids with human cDNA generated from a range of tissues, preferentially also testis tissue, inserted into the vector pACT2 (Clontech). Libraries are preferentially purchased from Clontech Laboratories (MATCHMAKER human cDNA libraries) and include Cat. numbers HL4040AH (aorta), HL4041AH (chondrocytes), HY4004AH (brain), preferentially also HY4035AH (testis), HY4024AH (liver), HY4042AH (heart), HY4053AH (bone marrow) and HY4028AH (fetal brain). The two-hybrid screens are essentially performed following the Clontech"Pretransformed Matchmaker Libraries User Manual" (PT3183-1): Transformed CG1945 and Y187 cells are mated in order to co-express the Gal4 :: PXR fusion protein and the Gal4AD fusion proteins encoded on the library plasmids within one cell. Interaction of the two hybrid proteins leads to activation of reporter gene transcription. Cells are selected for interactions of CF7 or CF8 with library proteins on medium lacking tryptophan, leucine and histidine and are further

assayed for expression of a-galactosidase, encoded by the MEL1 reporter gene.

Colonies that are positive for reporter gene activation are chosen for further analysis.

The DNA inserts of the library plasmids contained in these colonies are amplified by use of the polymerase chain reaction directly on the yeast colonies using oligonucleotide primer which hybridize on vector sequences flanking both sides of the insert. The identity of the insert is determined by standard DNA sequencing techniques. Mating experiments may be performed with the RevErb protein as well as with a thyroid hormone receptor.

EXAMPLE5 : DETECTION OF MUTANT ALLELES OF THE CF7 AND/OR CF8 GENEACCORDING TO THE INVENTION AND ITS UTILISATION FOR DIAGNOSTIC PURPOSES.

According to the diagnostic and prognostic method of the present invention, alteration of the wild-type cofactor gene is detected. In addition, the method can be performed by detecting the wild-type cofactor gene and confirming the lack of cause of the disease as a result of the locus.

"Alteration of the wild-type gene"encompasses all forms of mutations including deletions, insertions and point mutations in the coding and non-coding regions.

Deletions may be of the entire gene or of only a portion. Point mutations may result in stop codons, frameshift mutations or amino acid substitutions. Somatic mutations are those which occur only in certain tissues and are not inherited in the germline.

Germline mutations can be found in any of a body's tissue and are mostly inherited.

Point mutational events may occur in regulatory regions, such as the promotor of the gene, leading to loss or diminution of expression of the mRNA. Point mutations may also abolish proper RNA processing, leading to loss of expression of the cofactor gene product or to a decrease in mRNA stability or translation efficiency.

Applicable diagnostic techniques include, but are not limited to fluorescent in situ hybridization (FISH), direct DNA sequencing, PFGE analysis, Southern blot analysis, single stranded conformation analysis (SSCA), RNAse protection assay, allele- specific oligonucleotide (ASO), dot blot analysis, hybridization using nucleic acid

modified with gold nanoparticles and PCR-SSCP, as discussed in detail further below. Furthermore, DNA microchip technology can be applied.

The presence of a disease due to a germline mutation of the cofactor can be ascertained by testing any tissue of the diseased human for mutations of the cofactor gene. For instance, a person who has inherited a germline mutation in the cofactor gene, especially one that will alter the interaction of the cofactor with its nuclear receptor protein, will be prone to develop a disease. The presence of such a mutation can be determined by extracting DNA from any tissue of the body. For example, blood can be drawn and DNA extracted from blood cells and analyzed. Moreover, prenatal diagnosis of the disease will be possible by testing fetal cells, placenta cells or amniotic cells for mutations in the cofactor gene. There are several methods that allow the detection of alterations of the wild-typ cofactor gene, including for instance point mutations as well as deletions in the DNA sequence and these methods are discussed here: Direct genomic DNA Sequencing, either manual or by automated means can detect sequence variations of the cofactor gene (Nucleic Acids Res 1997 May 15; 25 (10): 2032-2034 Direct DNA sequence determination from total genomic DNA.

Kilger C, Paabo S, Biol. Chem. 1997 Feb; 378 (2): 99-105, Direct exponential amplification and sequencing (DEXAS) of genomic DNA. Kilger C, Paabo S, DE 19653439.9 and DE 19653494.1). Another way is to make use of the single-stranded conformation polymorphism assay (SSCP; Orita et al., PNAS 86,2766 (1989)).

Variations in the DNA sequence of the cofactor gene from the wild-type sequence will be detected due to a shifted mobility of the corresponding DNA-fragments in SSCP gels.

Other approaches are based on the detection of mismatches between the two complementary DNA strands. These methods, which will not allow the detection of large deletions, duplications or insertions nor the detection of a regulatory mutation affecting transcription or translation of the cofactor gene include the clamped denaturing gel electrophoresis (CDGE; Sheffield et al., 1991), heteroduplex analysis (HA; White et al., Genomics 4,560 (1992)) and chemical mismatch cleavage (CMC; Grompe et al., 1989). Other methods detect specific types of mutations such as

deletions, duplications or insertions, for instance a protein truncation assay or the asymmetric assay. These assay however, will not detect missense mutations. A review of currently available methods of detecting DNA sequence variation can be found in a review by Grompe, Nature Genetics 5,111 (1993). Once a mutation is known, an allele specific detection approach such as allele specific oligonucleotide (ASO) hybridisation will allow the rapid screening of a large number of other sample for that mutation. Such a technique may involve the utilization of probes which are labeled with gold nanoparticles to yield a visual color result (Elghanian et al., Science 277,1078 (1997)).

In another embodiment of the present invention large scale genetic studies might be applied to investigate the association of a disease-phenotype with the CF7 or CF8 gene. The availability of the human genome allows an easy definition of genetic markers for most genes for a particular disease physiology. More importantly, single nucleotide polymorphisms (SNPs) are amenable markers for large genetic studies.

SNPs in coding or regulatory regions of genes which are thought to contribute to a disease physiology can have a direct impact on the phenotype, e. g. change a quantitative readout of disease physiology, for example the age of onset of heart attack. Association and linkage studies with related individuals, therefore provide an excellent means to test or verify a hypothesis on the functional impact of the CF7 gene or CF8 gene on disease physiology in vivo, in humans.

In order to detect polymorphisms in DNA sequences, DNA samples can be prepared from normal individuals and from persons being affected by the disease and these samples can be cut by one or more restriction enzymes and applied to Southern analysis. Southern blots displaying hybridizing fragments differing in length from the control DNA when probed with sequences near or including the cofactor locus could indicate a possible mutation. If large DNA fragments are used it is appropriate to separate these fragments by pulsed field gel electrophoresis (PFGE).

Detection of point mutations may be accomplished by amplification, for instance by PCR, from genomic or cDNA and sequencing of the amplified nucleic or by molecular cloning of the cofactor allele and sequencing the allele using techniques well known in the art.

There are six well known methods for a more complete, yet still indirect, test for confirming the presence of a susceptibility allele : 1) single stranded conformation analysis (SSCP) (Orita et al., PNAS, 86,2766 (1989)); 2) denaturing gradient gel electrophoresis (DGGE) (Wartell et al., NAR 18,2699, (1990); Sheffield et al., PNAS 86,232 (1989)); 3) RNase protection assays (Finkelstein et al., Genomics 7,167 (1990); Kinszler et al., Science 251,1366 (1991)); 4) allele specific oligonucleotides (ASOs, Conner et al., PNAS, 80,278 (1983)); 5) the use of proteins which recognise nucleotide mismatches, such as the E. coli mutS protein (Modrich, Ann. Rev.

Genetics, 25,229 (1991)) and 6) allele-specific PCR (Ruano and Kidd, NAR 17,8392 (1989)). For allele-specific PCR, primers are used which hybridize at their 3'ends to a particular cofactor mutation. Without the mutation, no PCR product is observed.

Amplification Refractory Mutation System could also be used, as disclosed in European Patent Application Publication No. 0332435 and in Newton et al., NAR 17, 2503 (1989). Insertions and deletions of genes can also be detected by molecular cloning, amplification and sequencing. Moreover, restriction fragment length polymorphism (RFLP) probes for the gene or surrounding marker genes can be used to score for alteration of an allele or an insertion in a polymorphic fragment. Such a method would be particularly useful for screening relatives of an affected person for the presence of the mutation found in that person. Other approaches for detecting insertions and deletions as known for those trained in the art can be used.

SSCP detects a band which migrates differently because the variation causes a difference in single strand, intra molecular base pairing. The RNAse protection assay involves cleavage of the mutant fragment into two or more smaller fragments. By using DGGE variations in the DNA can be detected by differences in the migration rates of mutant compared to normal alleles in a denaturing gradient gel. In the mutS assay, the protein binds only to sequences that contain a nucleotide mismatch in a hetero duplex between mutant and wild-type sequences.

Mismatches, according to the present invention, are hybridised nucleic acid duplexes in which the two strands are not 100% complementary. Lack of total homology may be due to deletions, insertions, inversions or substitutions. Mismatch detection can be used to detect point mutations in the gene or the corresponding mRNA product.

While these techniques are less sensitive than sequencing, they can preferably be used when a large number of samples shall be tested. An example of the a mismatch cleavage method is the RNAse protection assay. In the practice of the present invention, the method involves the use of a labeled ribonucleotide probe which is complementary to the wild-type sequence of the cofactor gene coding sequence. The riboprobe and either mRNA or DNA isolated from the person are hybridised together and subsequently digested with the enzyme RNase A which is able to detect some mismatches in a duplex RNA structure. If a mismatch is detected by the enzyme, it cleaves at the site of the mismatch. Consequently, when the annealed RNA preparation is separated on an electrophoretic gel matrix, if a mismatch has been detected and cleaved by RNAse A, an RNA product will be seen which is smaller than the full length duplex RNA for the riboprobe and the mRNA or DNA. If the riboprobe comprises only a fragment of the mRNA or the gene, it is advantageous to use a number of probes to screen the whole mRNA sequence for mismatches.

Similarly, DNA probes can be used to detect mismatch mutations through enzymatic or chemical cleavage (Cotton et al., PNAS 85,4397 (1988); Shenk et al., PNAS 72, 989 (1975); Novack et al., PNAS 83,586 (1986)). Alternatively, mismatches can be detected by shifts in the electrophoretic mobility of mismatched duplexes relative to match duplexes (Cariello, Human Genetics 42, 726 (1988)). With either riboprobes or DNA probes, the cellular mRNA or DNA which might contain a mutation can be amplified using PCR (see below) before hybridization. Variations in DNA of the cofactor) gene can also be detected using Southern hybridization, especially if the changes are major rearrangements, such as deletions or insertions. DNA sequences of the cofactor gene which have been amplified by PCR may also be screened using allele specific probes. These probes are nucleic acid oligomers, each of which contains a region of the gene sequence harboring a known mutation. For instance, one oligomer could be about 25 nucleotides in length corresponding to a portion of the gene sequence. By using a number of such allele-specific probes, PCR amplification products can be screened to identify the presence of a previously discovered mutation in the gene. Hybridization of allele-specific probes with amplified cofactor sequence can be performed, for example, on a nylon filter. Under high stringency hybridisation conditions, the hybridisation of a particular probe should

indicate the presence of the same mutation in the tissue as in the allele-specific probe.

The newly developed technique of nucleic acid analysis via microchip technology is also applicable to the present invention. In this technique, thousands of distinct nucleotide probes are built up in an array on a silicon chip. Nucleic acid to be analyzed is fluorescently labeled and hybridised to the probes on the chip. It is also possible to study nucleic acid-protein interactions using these nucleic acid microchips. Using this technique one can determine the presence of mutations or even sequence the nucleic acid being analyzed or one can measure expression of a gene of interest. This method is one of parallel processing of thousands of probes at once and can tremendously accelerate the analysis. In several publications the use of this method is described (Hacia et al., Nature Genetics 14,441 (1996); Shoemaker et al., Nature Genetics 14,450 (1996); Chee et al., Science 274,610 (1996); DeRisi et al., Nature Genetics 14,457 (1996)). This new technology has also been reviewed in Borman et al., Chemical and Engineering News 9,42 (1996) and has been subject of an editorial in Nature Genetics (1996).

The most definite test for mutations in a candidate locus is to directly compare the genomic cofactor sequence from patients with those from normal individuals.

Alternatively one could sequence mRNA after amplification (for example by PCR) thereby eliminating the necessity of determining the exon structure of the respective gene.

Mutations from patients falling outside the coding region of the cofactor gene can be detected by examining the non-coding regions, such as introns and regulatory sequences within or near the CF7 or CF8 gene. Early indications of mutations in noncoding regions could be for example the abundance or abnormal size of mRNA products in patients as compared to control individuals as detected by northern blot analysis.

Alteration of cofactor expression can be detected by any techniques known in the art.

These include northern blot analysis, PCR amplification and RNAse protection.

Diminished mRNA expression indicates an alteration in the wild-type gene sequence.

Alterations of wild-type genes can also be detected by screening for alteration of cofactor protein. For example, monoclonal antibodies against cofactor protein can be used to screen a tissue. Lack of cognate antigen would indicate a mutation.

Antibodies specific for products of mutant alleles can also be used to detect mutant gene product. These kind of immunological assays can be done in any convenient format known in the art. These include western blots, immunohistochemical assays and ELISA assays. Any means for detecting an altered cofactor protein can be used to detect alteration of the wild-type cofactor gene. Functional assays such as protein binding determinations can be used. Moreover, assays can be used which detect the cofactor's biochemical function. Finding the mutant cofactor gene product indicates an alteration of the cofactor wild-type gene. One such binding assay would test the binding of cofactor protein (CF7 or CF8) with wild-type nuclear receptor protein.

Conversely, wild-type nuclear receptor protein or the domain interacting with the cofactor protein can be used in a protein binding assay or biochemical function assay to detect normal or mutant nuclear receptor proteins.

A mutant cofactor gene or gene product or a mutant nuclear receptor protein can also be detected in other human body samples, such as serum, stool, urine and sputum. The same techniques discussed above for detection of mutant genes or gene products in tissues can be applied to other body samples. By screening such body samples, a simple early diagnosis can be achieved for the disease) resulting from a mutation in the cofactor gene.

EXAMPLE 6: A CELL BASED ASSAY FOR MEASURING THE BINDING OF THE COFACTOR TO THE NUCLEAR RECEPTOR.

The DNA sequence encoding the open reading frame of the cofactor (CF7 or CF8) is transferred into the vector pVP16 (Clontech) to allow the expression of a fusion protein of the cofactor with the strong transactivation domain of the VP16 protein (of herpex simplex virus) in mammalian cells under the control of the strong CMV promoter. On another vector (the reporter), the luciferase gene is cloned under the control of a minimal promoter containing a nuclear receptor-responsive DNA element. This vector also expresses a second enzyme, e. g. beta-galactosidase, under the control of a constutuive promoter, to allow normalisation for transfection

efficiency between experiments. A third vector contains the nuclear receptor gene under the control of the strong CMV promoter.

CV-1 cells are then transiently transfected with different combinations of the three plasmids. Transfection is done by standard methods, e. g. by use of the CalPhos Maximizer (Clontech, #8021-1,-2). Interaction of the cofactor protein with the nuclear receptor will lead to a strong transactivation due to the attached VP16 domain of the cofactor fusion protein. Thus, interaction of the cofactor with the nuclear receptor will result in increased luciferase activity. Thus, inclusion of the cofactor VP16 will result in increased luciferase activity as compared to transfection of the nuclear receptor and the reporter alone. To measure this effect, extracts are prepared of the transfected cells 48 to 72 hours after transfection, and luciferase activity is determined. To normalize for transfection efficiency, beta-galactosidase activity is also determined.

Addition of substances known or suspected to influence the binding of the nuclear receptor to the cofactor CF7 or CF8 respectively are added to the medium of the transfected cells. These substances are added at different time points prior to cell lysis, typically ranging between 18 hours to a five minutes before cell lysis. Luciferase activity is taken as a measure of the effect of these substances on the binding of the cofactor to the nuclear receptor. To avoid activation of the nuclear receptor by substances contained in the serum of the medium, charcoal-stripped serum has to be used for these experiments.

In an alternative setting of the experiment, the DNA-binding domain of the nuclear receptor is replaced with the DNA-binding domain of the yeast GAL4 transcription factor. On the reporter plasmid, the luciferase is expressed under the control of GAL4-responsive upstream activating sequences. Expression of luciferase again is an indication for binding of the cofactor CF7-VP16 fusion or CF8-VP16 fusion to the nuclear receptor-GAL4 fusion. This setting is also referred to as the mammalian two hybrid system. A description of the experiment is found in the manual to the Mammalian MATCHMAKER Two-Hybrid Assay Kit from Clontech, # PT3002-1, catalogue #K1602-1)

In an alternative setting, the plasmid directing expression of the VP16-cofactor chimeric protein is replaced by a plasmid directing the expression of the native cofactor protein. This is useful if the native cofactor protein has an effect on the transcriptional activity of the nuclear receptor. This effect can then be measured by measuring the amount of luciferase produced. This effect can be both positive, leading to more luciferase produced, or negative, leading the expression of less luciferase protein.

Substances activating nuclear receptors cause an exchange of the proteins bound to the receptors, thus effecting the dissociation of some proteins and promoting the binding of other proteins. Thus, in the experiments as described above, one can test for nuclear receptor-activating compounds and nuclear receptor-inactivating compounds by monitoring the binding of the CF7 (or CF8) cofactor to the nuclear receptor.

In an alternative setting, stably transfected cell lines are used which contain copies of the two different expression constructs for the nuclear receptor and the CF7 cofactor as well as the reporter construct stably integrated into the chromosomes of the cells.

EXAMPLE 7: A FRET ASSAY USING CF7 OR CF8 COFACTOR PROTEIN DNA sequences encoding the open reading frame of the cofactor and the nuclear receptor gene are each transferred separately into the vector pENTRY (Life Technologies) to allow efficient construction of a diverse set of expression constructs.

The open reading frame is then recombined into the vector pDEST17 for expression in E. coli strain BL21 as a fusion protein to a six-histidine tag induced by IPTG, as well as into the pDEST15 for expression as a fusion protein with glutathione S- transferase (GST). The plasmids pDEST15, pDEST17and pENTRY are purchased from LIFE TECHNOLOGIES. Alternatively, the open reading frame is introduced into the vector pLV-CBDgw for expression as a fusion protein with the calmodulin binding protein using recombinant baculoviruses as specified by the manufacturer (Becton Dickinson). pLV-CBDgw is a derivative of the vector pLV1392 (Becton Dickinson) which is modified by the insertion of a calmodulin binding protein fragment, followed by the sequence required for recombinational cloning via the Gateway system (Life

Technologies). Protein expression is induced and recombinant protein is purified by passage over a Ni-NTA-column, or a glutathione column or a calmodulin column, respectively.

To measure the interaction of the two proteins, a biotinylated (Biotintag Micro biotinylation Kit, Sigma) His-tagged nuclear receptor protein and the GST fusion of the CF7 (or CF8) cofactor are mixed at 0.2-5 uM. Antibody to the GST protein is added which is labelled by the europium chelate at a concentration of 1-3 (typical 2.5) nM. Streptavidin which is fluorescently labeled by covalent attachment of allophycocyanin is added at a concentration of 5-30 ug/ml (typical 10, ug/ml). The europium chelate is stimulated by a flash of light (320nm) and, the emitted light is measured in a delayed (50-200 us) time window for 300 to 600 us after the flash at 615 nm (fluorescence of europium chelate) and 655nm (fluorescence of APC). Since APC is only excited by the light emitted by the europium chelate, a close proximity of the two different fluorophores is required for excitation. The strength of the APC signal, as well as the ratio of the signals from the two fluorophores (i. e. the ratio of the intensities of light emitted at 655 and 615nm) serves as a measure for the interaction of the two proteins. Reaction buffers contain 20mM TrisHCI pH 7.9,60mM KCI, 4mM MgCl2. Reaction volume is 25ul. The Wallac VictorV fluorimeter is used for the fluorimetric measurements.

In an alternative setting, the cofactor is used as a biotinylated His-tagged protein, and the nuclear receptor protein is used as fusion to GST. In yet another setting, the His- tagged proteins are replaced by the same proteins fused to the calmodulin binding protein. In the latter case, the detection of the interaction is via biotinylated calmodulin, which is in turn binding to APC-coupled streptavidin. Calcium has to be included in the buffer in the form of 4mM CaCI2, to allow complex formation between calmodulin and the calmodulin binding protein.

EXAMPLE 8: NORTHERN ANALYSIS: Northern analysis is performed on total cellular RNA as described in (Kallen, C. B. & Lazar, M. A. (1996) Proc. Natl. Acad. Sci. USA 93,5793-5796) using cDNA probes

for CF7 and CF8. The full-length probes are used containing the coding region (see Fig. 4). Probes were labeled with 32P using random primers (Boehringer Mannheim).

EXAMPLE 9 : IMMUNOFLUORESCENCE : 293T cells grown on glass coverslips are transfected with 20 pg of vector containing hemagglutinin (HA)-tagged CF7/CF8 by the calcium phosphate precipitation method.

Two days posttransfection, the cells are fixed for 30 min in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, and blocked with 1% nonfat dry milk in PBS. Cells are incubated with a 1: 75 dilution of anti-HA (monoclonal 12CA5) and anti-CF7 or 8 (polyclonal rabbit serum raised against GST-CF7 or 8) antibodies for 1 h in a humid chamber at 37°C. After washing with PBS, rhodamine conjugated donkey anti-rabbit and fluorescein-conjugated donkey anti-mouse secondary antibodies are applied at 1: 200 dilution for 1 h at 37°C. Cells are washed in PBS and mounted prior to photography.

EXAMPLE 10: COIMMUNOPRECIPITATION AND WESTERN ANALYSIS : C2C12 cells are harvested on days 0-4 of differentiation, and equal quantities of protein are separated by SDS-PAGE and transferred to nitrocellulose.

Immunoblotting is performed with polyclonal anti-CF7 or CF8 antibody at a 1: 400 dilution followed by detection with the ECL reagent system (Amersham).

Immunoprecipitation assays are performed in HeLa, 293, and CV-1 cells transfected with both CF7 or CF8 protein and RevErb (10 ug per 150-mm plate) or CF7 or CF8 alone and lysed with NETN buffer (300 mM NaCI/0. 5% Nonidet P-40) containing protease inhibitors. Whole cell extracts are clarified by centrifugation, and equal quantities of protein are immunoprecipitated at 0°C for 1 h with 5 ul of anti-RevErb (Dumas, B., Harding, H., Choi, H.-S., Lehmann, K., Chung, M., Lazar, M. A. & Moore, D. D. (1994) Mol. Endocrinol. 8,996-1005) or anti-CF antibodies or2 pl of monoclonal anti-HA antibody (12CA5).

Immunoprecipitation reactions are then incubated with protein-A/G agarosebeads (Santa Cruz Biotechnology) for 1 h at 4°C. Samples are washed with NETN buffer, boiled, separated by SDS-PAGE, and transferred to nitrocellulose. Immunoblotting is performed with anti-HA antibody at 1: 500 dilution or anti-RevErb monoclonal antibody at 1: 400 followed by detection by ECL reagent.

EXAMPLE 11 PROTEIN BINDING ASSAYS USING GST FUSION PROTEINS : GST fusion proteins are prepared as previously described in Zamir, I., Harding, H. P., Atkins, G. B., Horlein, A., Glass, C. K., Rosenfeld, M. G. & Lazar, M. A. (1996) Mol.

Cell. Biol. 16,5458-5465. GST beads (50 pI) containing the fusion protein are incubated at room temperature in a buffer containing 50 mM KCI, 20 mM Hepes, pH 7.9,2 mM EDTA, 0.1% Nonidet P-40,10% glycerol, 0.5% nonfat dry milk, and 5 mM DTT. Five microliters of in vitro translated RevErb, CF7, CF8, or Luciferase is added to the beads (input was 1 NI). Binding is allowed to proceed for 1 h, and the beads are washed four times in the same buffer. The bound proteins are eluted by boiling in 30 ut of SDS-PAGE loading buffer and resolved by electrophoresis. The GST fusion proteins are stained with Coomassie to ensure equal loading, and the bound proteins are visualized by autoradiography.

FIGURE CAPTIONS : Figure 1: Fig. 1 depicts the cDNA sequence of CF7 and CF8 as well as primers which may be used to amplify the cDNA sequences.

Figure 2: Fig. 2 depicts the reverse complement of the cDNA (s) according to the invention.

Figure 3: Fig. 3 depicts the protein sequence of CF7 and CF8.

Fig. 4: Fig. 4 depicts the sequence numbering and the corresponding SEQ IN Numbers.




 
Previous Patent: MIXED FIBRILS

Next Patent: FLUORESCENT PROTEINS